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5',UCCAUG,tl.CG UUCG./GAQWJ UUlHJUU!,)tl(J~ GU(:{iUl,UUGC ,1\UUCCGP~,jEQ lD NO: l 6 
5'-·-UCC:AUG.::.\f§;U UCOJGACGUU UUUUUCCAUl, CCGCUMUUC CAA.CU,ti.-35EQ ID NO: 18 
S'··UCCAUGt.-{..:;-.§U UCCUGA[:,f£UU UUUUUµ.J,,.GtA U.\UGCG;:.\UGU UUAACl-"iEQ ID NO: 20 
HG.56 
l\21. Cot, R Ni4, 
., 
* 5} -UCCAUGACG UUCCUGACGU UUUUUUUACA 
G UCGUAU UGC AU UCCGA-3' 46 SEQ ID NO: 16 
• DNA : TAA TAC GAC TCA CTATA TCC ATG ACG 
TTC CTG ACG TTT TTT T TAC AGT CGT ATT GCA 
TTC CGA 63nt sEQroNo: 2s 
• 5' Pdmer: TAA TAC GAC TCA CTATA TCC ATG 
ACG TTC CTG ACG TTT SEQ ID NO: 26 
~ !f Primer: TCGGAATGCA ATACGACTGT 
AAAAAAAACG TCAGGAA SEQ ID NO: 27 
I--'IG. 57 
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~ 5'-UCCAUGACGU UCCUGACGUU UUUUUCCAUA 
CCGCCAUUUC CAACUA-3} 46n __ sEQIDNo: rn 
# DNA: TAA TAC GAC TCA CTATA TCC ATG ACG TTC 
CTG ACG TTT TTT T CCA TAC CGC CAT TIC CAA 
CTA 63n1 sEQ 10 No: 2s 
~ 5' Primer: TAA TAC GAC TCA CTATA TCC ATG ACG 
TIC CTG ACG TTT SEQ ID NO: 29 
~ 31 Primer: TAGTTGGAAA TGGCGGTATG 
GAAAAAAACG TCAGGAA SEQ ID NO: 30 
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81 51-UCCAUGACGU UCCUGACGUU UUUUUAAGCA 
CAUGCGAUGU UUAACU-3" 46n sEQIDNo:20 
# DNA: TAA TAC GAC TCA CTATA TCC ATG ACG TTC 
CTG ACG TTT TIT T AAG CAC ATG CGA TGT TTA 
ACT 63nt sEQ10No:J1 
si 5' Primer: TAA TAC GAC TCA CTATA TCC ATG ACG 
TIC CTG ACG TTT SEQ ID NO: 32 
# 3' Primer: AGTTAAACAT CGCATGTGCT 
TAAAAAAACG TCAGGAA SEQ lD NO: 33 
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RNA-BASED COMPOSITIONS AND 
ADJUVANTS FOR PROPHYLACTIC AND 
THERAPEUTIC TREATMENT 
RELATED APPLICATIONS 
This application is a continuation-in-part of PCT appli-
cation No. PCT/US2015/036798, filed Jun. 19, 2015, which 
claims priority of U.S. Provisional Patent Application No. 
62/014,503, filed Jun. 19, 2014, and the entire disclosures of 
which are hereby incorporated by reference in their entire-
ties. 
GOVERNMENT INTEREST 
This invention was made with govermnent support under 
EB003730, EB 012135, and CA 151648 awarded by the 
National Institutes of Health. The govermnent has certain 
rights in the invention. 
SEQUENCE LISTING 
The instant application contains a Sequence Listing which 
has been submitted electronically in ASCII format and is 
hereby incorporated by reference in its entirety. Said ASCII 
copy, created on Feb. 23, 2017, is named 2935720-000002 
SL.txt and is 25,100 bytes in size. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to RNA-
based compositions, including immunostimulatory RNA-
containing compositions and RNA nanoparticle-containing 
compositions, methods of making the compositions, and use 
of RNA-based adjuvants for prophylactic and therapeutic 
treatment. 
INTRODUCTION 
2 
excessive repetition, this Summary does not list or suggest 
all possible combinations of such features. 
The presently-disclosed subject matter comprises RNA 
that can be used as a construction material, immunostimu-
5 latory agent, or a combination thereof for the development 
of new nanovaccines and adjuvants for disease prevention 
and treatment. 
The presently-disclosed subject matter comprises a com-
position which is comprised of an RNA-oligonucleotide, 
10 which can be single-stranded or double stranded, and an 
immunostimulatory motif. 
In some embodiments, the RNA-oligonucleotide com-
prises a chemical modification. In some preferred embodi-
ments, the chemical modification is selected from 2'Fluoro, 
15 2'Amine, and 2'O-Methyl. In some embodiments, the RNA-
oligonucleotide is about 8-50 bases in length. In some 
embodiments, the RNA-oligonucleotide is partially double 
stranded, for example containing a hair-pin. 
In some embodiments, the immunostimulatory motif is 
20 immunostimulatory RNA or a CpG oligodeoxyribonucle-
otide. In some embodiments, the immunostimulatory motif 
is conjugated to the RNA-oligonucleotide. In some embodi-
ments the immunostimulatory motif is oligodeoxyribonucle-
otide. In some embodiments, the composition is provided as 
25 an adjuvant. 
The presently-disclosed subject matter comprises an arti-
ficial RNA nanostructure comprising multiple external 
strands and one internal strand, wherein the external strands 
and internal strand self-assemble to form a nanostructure. In 
30 some embodiments, the multiple external strands can, for 
example, be 3, 4, or 5 strands. In some embodiments, the 
external strands comprise about 48 nucleotides; and in some 
preferred embodiments, the nanostructure comprises a 
pRNA3WJ motif at each vertex. In some embodiments, the 
35 external strands comprise more than 48 nucleotides. In some 
embodiments, the external strands comprise less than 48 
nucleotides. In some embodiments, the external strands 
comprise about 10, about 20, about 30, about 40, about 50, 
Cancer and infectious diseases such as influenza and 40 
about 60, about 70, about 80, about 90, about 100 nucleo-
tides. 
In some embodiments the artificial RNA nanostructure 
comprises a triangle and has a stretched intrahelical angle 
between about Hl and H2. In other embodiments, the 
nanostructure comprises a square and has a stretched intra-
helical angle between about Hl and H2. In other embodi-
ments, nanostructure comprises a pentagon and has a 
stretched intrahelical angle between about Hl and H2. In 
some embodiments, the RNA nanostructure comprises an 
RNA triangle, RNA square, RNA pentagon, RNA hexagon, 
human immunodeficiency virus infection/acquired immuno-
deficiency syndrome (HIV/AIDS) are still a huge threat to 
public health world-wide. Prophylactic and treatment vac-
cines could offer promising opportunities for controlling 
these diseases. However, despite tens of years of extensive 45 
research, such vaccines are still far away from completely 
controlling these diseases due to either low effectiveness or 
safety issues. New strategies and approaches in designing 
and developing new vaccines and adjuvants targeting these 
diseases are urgently needed. 50 RNA three-way junction, and RNA four-way junction. In 
some embodiments, the RNA nanostructure is derived from 
a 3WJ motif. In some embodiments, the RNAnanostructure 
comprises a stretched intrahelical angle between about Hl 
SUMMARY 
The presently-disclosed subject matter meets some or all and H2, as exemplified in FIG. 1. 
of the needs as described herein, as will become evident to 55 
those of ordinary skill in the art after a study of information 
In some embodiments, the subject matter relates to a 
composition comprising an RNA nanostructure that com-
prises an adjuvant, an antigen, and/or a targeting ligand. In 
some embodiments, the composition induces an immune 
response. In some embodiments, the immune response 
as described herein. 
This S=ary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
Summary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative fea-
tures of a given embodiment is likewise exemplary. Such an 
embodiment can typically exist with or without the 
feature(s) mentioned; likewise, those features can be applied 
to other embodiments of the presently-disclosed subject 
matter, whether listed in this Summary or not. To avoid 
60 increases cytokine at least ten fold as compared to the 
adjuvant, the antigen, and/or the targeting ligand provided 
independently of the RNA nano structure. In some embodi-
ments, the adjuvant comprises a composition comprising an 
RNA-oligonucleotide and an immunostimulatory motif. In 
65 some embodiments, the RNA-oligonucleotide and immuno-
stimulatory motif are incorporated into the RNA nanopar-
ticle by the RNA-oligonucleotide being covalently bonded 
US 10,378,018 B2 
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position comprising an RNA nanostructure and an adjuvant, 
an antigen, and/or a targeting ligand. 
Embodiments as described herein comprise a method of 
inducing the production of cytokines. In some embodiments, 
to an RNA strand of the RNA nanoparticle. Non-limiting 
examples of the bond between RNA-oligonucleotide and the 
RNA strand of the RNA nanoparticle is ionic bond or 
hydrogen bond. In some embodiments, the RNA-oligo-
nucleotide and immunostimulatory motif are incorporated 
into the RNA nanoparticle by base pairing between the 
RNA-oligonucleotide and the RNA nanoparticle. In some 
embodiments, the adjuvant comprises an immunostimula-
tory RNA (isRNA), and in some embodiments the adjuvant 
comprises a CpG oligodeoxyribonucleotide. In some 
embodiments, the adjuvant comprises isRNA that is about 8 
5 the cytokines comprise TNF-alpha, IL-6, IL-12, or a com-
bination thereof. In some embodiments, the method com-
prises administering an RNA-oligonucleotide and an immu-
nostimulatory motif. In some embodiments, the production 
of cytokines is increased at least ten fold as compared to the 
10 immunostimulatory motif provided independently of the 
RNA-oligonucleotide. 
to about 50 bases in length. In some embodiments, the 
adjuvant comprises isRNA that is less than 8 bases in length. 
In some embodiments, the method comprises administer-
ing a composition comprising an RNA nano structure and an 
adjuvant, an antigen, a targeting ligand, or a combination of 
In some embodiments, the adjuvant comprises isRNA that is 
more than 50 bases in length. In some embodiments, the 
adjuvant comprises isRNA that is about 1, about 2, about 3, 
about 4, about 5, about 6, about 7, about 8, about 9, about 
15 the adjuvant, ligand, or targeting ligand. In some embodi-
ments, the induction of the production of cytokines is 
increased at least ten fold as compared to the adjuvant, the 
antigen, and/or the targeting ligand provided independently 
10, about 20, about 30, about 40, about 50, about 60, about 
70, about 80, about 90, about 100 bases in length. In some 20 
embodiments, the adjuvant is CpG RNA. In some embodi-
ments, the adjuvant is covalently bonded to an RNA strand 
of the RNA nanostructure. 
In some embodiments, administering a composition as 
described herein to a subject induces the production of high 
affinity neutralizing antibodies or inhibitory antibodies. In 
some embodiments, the subject has or is at risk of having a 
pathological condition. In some embodiments, the patho-
of the RNA nanoparticle. In other embodiments, the adju-
vant is incorporated into the RNA nanoparticle by base 
pairing. 
Embodiments as described herein comprise one or more 
of the sequences of SEQ ID NOS: 16-24. In one embodi-
ment, the oligonucleotide has at least 60%, at least 65%, at 
least 70%, at least 80%, at least 85%, at least 90%, at least 
25 logical condition comprises cancer, human immunodefi-
ciency virus (HIV), influenza, drug and substance abuse, or 
a combination thereof. 
91 %, at least 92%, at least 93%, at least 94%, at least 95%, 30 
at least 96%, at least 97%, at least 98%, at least 99%, or 
100% identity to a nucleic acid sequence comprising SEQ 
ID NOS: 16-24. In one embodiment, the oligonucleotide has 
at least 60%, at least 65%, at least 70%, at least 80%, at least 
85%, at least 90%, at least 91 %, at least 92%, at least 93%, 35 
at least 94%, at least 95%, at least 96%, at least 97%, at least 
98%, at least 99%, or 100% similarity to a nucleic acid 
sequence comprising SEQ ID NOS: 16-24. 
In some embodiments, the RNA nanostructure comprises 
an antigen. In some embodiments, the antigen is derived 40 
from a bacteria, virus, or cell. In some embodiments, the 
antigen binds to a neutralizing antibody or an inhibitory 
antibody. In some embodiments, the antigen comprises a 
neutralizing epitope. In some embodiments, the antigen 
comprises B-cell epitope, T-cell epitope, T-helper epitope, 45 
epitopes derived from PG120, gp41 epitopes, glycans, pep-
tides, T-helper peptides, streptavidin, or a combination 
thereof. 
In some embodiments, the RNA nanostructure comprises 
In some embodiments, embodiments as described herein 
are used for the manufacture of a medicament useful for the 
treatment of a pathological condition in a subject. In some 
embodiments, the medicament is used prophylactically. 
Embodiments as described herein also provide methods of 
making an RNA nanostructure. In some embodiments, the 
method of making an RNA nano structure comprises mixing 
equimolar concentrations of a multiple of external RNA 
strands, and one internal RNA strand to make a mixture, 
annealing the mixture, and cooling the mixture slowly. In 
some embodiments, the mixture is cooled at about 1 ° C. per 
minute. In some embodiments, the mixtures is cooled faster 
or slower than about 1 ° C. per minute. In some embodi-
ments, the mixture is cooled from about 80° C. to about 4 ° 
C. In some embodiments, the mixture is cooled to a tem-
perature greater than 80° C. In some embodiments, the 
mixture is cooled to a temperature less than 80° C. In some 
embodiments, the mixture is cooled to about 1 ° C., about 2° 
C., about 3° C., about 4° C., about 5° C., about 6° C., about 
7° C., about 8° C., about 9° C., about 10° C., about 20° C., 
about 30° C., about 40° C., about 50° C., about 60° C., or 
about 70° C. In some embodiments, the mixture is annealed 
50 for about one hour. In some embodiments, the mixture is 
annealed for more than one hour. In some embodiments, the 
mixture is annealed for less than one hour. In some embodi-
ments, the mixture is annealed for up to about 10, about 20, 
a targeting ligand. In some embodiments, the targeting 
ligand comprises an aptamer, a cell surface marker, folate, 
siRNA, shRNA, or a combination thereof. In some embodi-
ments, the aptamer binds to an HIV epitope. In other 
embodiments, the cell surface marker comprises a macro-
phage or lymphocyte. In some embodiments, the targeting 55 
ligand targets B cells, T cells, dendritic cells, macrophages, 
cancer cells, or a combination thereof. In some embodi-
ments, there are more than one targeting ligand. In some 
embodiments, the targeting ligands are the same. In other 
embodiments, the targeting ligands are not all the same. 
about 30, about 40, or about 50 minutes. In some embodi-
ments, the mixture is annealed for up to about 1, about 2, 
about3,about4,about5,about6,about 10,about 12,about 
18, or about 24 hours. In some embodiments, the method 
comprises modifying one or more of the external strands to 
comprise at least one antigen, at least one adjuvant, at least 
60 one targeting ligand, or a combination thereof. In some 
embodiments, there are optionally 3, 4, or 5 external strands. 
In some embodiments, the external strands comprise about 
48 nucleotides. In some embodiments, the external strands 
Embodiments as described herein comprise a method of 
inducing an immune response in a subject, comprising 
administering to the subject an effective amount of the 
compositions of the present invention. In some embodi-
ments, the method comprises administering an RNA-oligo- 65 
nucleotide and an immunostimulatory motif. In some 
embodiments, the method comprises administering a com-
comprise more than 48 nucleotides. In some embodiments, 
the external strands comprise less than 48 nucleotides. In 
some embodiments, the external strands comprise about 10, 
about 20, about 30, about 40, about 50, about 60, about 70, 
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about 80, about 90, about 100 nucleotides. In some embodi-
ments, the nanostructure produces by the method comprises 
a pRNA 3WJ motif at each vertex. In some methods, the 
nanostructure shape comprises a triangle, square and pen-
tagon. In some embodiments, the shapes produced by the 
method have a stretched intrahelical angle between about Hl 
and about H2. 
Embodiments as described herein comprise an RNA-
oligonucleotide and an immunostimulatory motif. In 
embodiments, the RNA oligonucleotide can be single-
stranded, double stranded, or partially double stranded. In 
embodiments, the RNA-oligonucleotide comprises a chemi-
cal modification, examples of which comprise 2'Fluoro, 
2'Amine, and 2'O-Methyl. In embodiments, the RNA oligo-
nucleotide comprises about 8 to about 50 bases in length. 
Embodiments as described herein comprise an immuno-
stimulatory motif. In embodiments, the immunostimulatory 
motif comprises an immunostimulatory RNA (isRNA), and 
a CpG oligodeoxyribonucleotide. In embodiments, the 
immunostimulatory motif can be conjugated to the RNA-
oligonucleotide. For example, the immunostimulatory motif 
is CpG oligodeoxyribonucleotide conjugated to the RNA-
oligonucleotide. For example, the isRNA is CpG RNA 
conjugated to the RNA-oligonucleotide. Embodiments as 
described herein can be provided as an adjuvant. 
Embodiments as described herein comprise the oligo-
nucleotide sequence of A21 CpG RNA (SEQ ID NO: 16), 
B21 CpG RNA (SEQ ID NO: 18), and C21 CpG RNA (SEQ 
ID NO: 20). Embodiments as described herein comprise one 
or more of the sequences of SEQ ID NOs 16-21. In one 
embodiment, the oligonucleotide has at least 60%, at least 
65%, at least 70%, at least 80%, at least 85%, at least 90%, 
at least 91 %, at least 92%, at least 93%, at least 94%, at least 
95%, at least 96%, at least 97%, at least 98%, at least 99%, 
or 100% identity to a nucleic acid sequence comprising SEQ 
ID Nos 16-21. In one embodiment, the oligonucleotide has 
at least 60%, at least 65%, at least 70%, at least 80%, at least 
85%, at least 90%, at least 91 %, at least 92%, at least 93%, 
at least 94%, at least 95%, at least 96%, at least 97%, at least 
98%, at least 99%, or 100% similarity to a nucleic acid 
sequence comprising SEQ ID Nos 16-21. 
Embodiments as described herein comprise an artificial 
RNA nanostructure comprising three, four, or five external 
strands of RNA. In embodiments, each external strand 
comprises about 40 to about 50 nucleotides; one internal 
strand of RNA, including more than about 50 nucleotides, 
the internal strands and external strands assembled to form 
6 
angle comprises greater than 108°. In other embodiments, 
the angle comprises less than 108°. 
Embodiments as described herein comprise one or more 
of the sequences of SEQ ID NOs 1-4. In one embodiment, 
5 the oligonucleotide has at least 60%, at least 65%, at least 
70%, at least 80%, at least 85%, at least 90%, at least 91 %, 
at least 92%, at least 93%, at least 94%, at least 95%, at least 
96%, at least 97%, at least 98%, at least 99%, or 100% 
identity to a nucleic acid sequence comprising SEQ ID Nos 
10 1-4. In one embodiment, the oligonucleotide has at least 
60%, at least 65%, at least 70%, at least 80%, at least 85%, 
at least 90%, at least 91 %, at least 92%, at least 93%, at least 
94%, at least 95%, at least 96%, at least 97%, at least 98%, 
at least 99%, or 100% similarity to a nucleic acid sequence 
15 comprising SEQ ID Nos 1-4. 
Embodiments as described herein comprise one or more 
of the sequences of SEQ ID NOs 5-9. In one embodiment, 
the oligonucleotide has at least 60%, at least 65%, at least 
70%, at least 80%, at least 85%, at least 90%, at least 91 %, 
20 at least 92%, at least 93%, at least 94%, at least 95%, at least 
96%, at least 97%, at least 98%, at least 99%, or 100% 
identity to a nucleic acid sequence comprising SEQ ID Nos 
5-9. In one embodiment, the oligonucleotide has at least 
60%, at least 65%, at least 70%, at least 80%, at least 85%, 
25 at least 90%, at least 91 %, at least 92%, at least 93%, at least 
94%, at least 95%, at least 96%, at least 97%, at least 98%, 
at least 99%, or 100% similarity to a nucleic acid sequence 
comprising SEQ ID Nos 5-9. 
Embodiments as described herein comprise one or more 
30 of the sequences of SEQ ID NOs 10-15. In one embodiment, 
the oligonucleotide has at least 60%, at least 65%, at least 
70%, at least 80%, at least 85%, at least 90%, at least 91 %, 
at least 92%, at least 93%, at least 94%, at least 95%, at least 
96%, at least 97%, at least 98%, at least 99%, or 100% 
35 identity to a nucleic acid sequence comprising SEQ ID Nos 
10-15. In one embodiment, the oligonucleotide has at least 
60%, at least 65%, at least 70%, at least 80%, at least 85%, 
at least 90%, at least 91 %, at least 92%, at least 93%, at least 
94%, at least 95%, at least 96%, at least 97%, at least 98%, 
40 at least 99%, or 100% similarity to a nucleic acid sequence 
comprising SEQ ID Nos 10-15. 
Embodiments as described herein comprise one or more 
immunostimulatory motifs as described herein. For 
example, such motifs comprise one or more immunostimu-
45 latory RNAs (isRNA) or CpG motifs. 
a triangle nanostructure, a square nanostructure, or a poly-
gon nanostructure; and a pRNA three-way junction (3WJ) 50 
motif at each vertex of the nanostructure. 
Embodiments as described herein comprise an RNA 
nanostructure as described herein, an adjuvant, an antigen, a 
targeting ligand, or a combination thereof. In embodiments, 
the RNA nanostructure comprises an RNA triangle, RNA 
square, RNA pentagon, RNA hexagon, RNA three-way 
junction, RNA four-way junction, or any combination 
In embodiments, the nanostructure comprises a triangle. thereof. Embodiments as described herein can be derived 
from a 3JW motif. In embodiments, the RNA nanostructure 
contains a stretched intrahelical angle between Hl and H2, 
In embodiments, the triangle has a stretched intrahelical 
angle between about Hl and about H2. In embodiments, the 
angle comprises about 60°. In embodiments, the angle 
comprises greater than 60°. In other embodiments, the angle 
comprises less than 60°. 
55 as described herein. 
In embodiments, the nanostructure comprises a square. In 
embodiments, the square has a stretched intrahelical angle 
between about Hl and about H2. In some embodiments, the 60 
angle comprises about 90°. In embodiments, the angle 
comprises greater than 90°. In other embodiments, the angle 
comprises less than 90°. 
In embodiments, the nanostructure comprises a pentagon. 
In embodiments, the pentagon has a stretched intrahelical 65 
angle between about Hl and about H2. In some embodi-
ments, the angle comprises about 100°. In embodiments, the 
In embodiments, the adjuvant comprises an immunos-
timulatory RNA (isRNA) and a CpG oligodeoxyribonucle-
otide (CpG). In embodiments, the isRNA comprises an 
oligonucleotide comprising about 8 to about 50 bases in 
length. 
In embodiments, the isRNA is incorporated into the RNA 
nanoparticle by being covalently bonded to an RNA strand 
of the RNA nanoparticle. In embodiments, the isRNA com-
prises CpG RNA. In embodiments, the CpG RNA comprises 
A21 CpG RNA (SEQ ID NO: 16), B21 CpG RNA (SEQ ID 
NO: 18), and C21 CpG RNA (SEQ ID NO: 20), as described 
herein. 
US 10,378,018 B2 
7 
In embodiments, the isRNA is incorporated into the RNA 
nanoparticle by base pairing. In embodiments, the isRNA 
comprises a CpG RNA. In embodiments, the CpG RNA 
comprises A21 CpG RNA (SEQ ID NO: 16), B21 CpG RNA 
(SEQ ID NO: 18), and C21 CpG RNA (SEQ ID NO: 20), as 
described herein. 
In embodiments, an adjuvant refers to a composition as 
described herein given in combination with an RNA nano-
structure to enhance its immunogenicity. 
In embodiments, the RNA-oligonucleotide and immuno-
stimulatory motif are incorporated into the RNA nanopar-
ticle by base pairing between the RNA-oligonucleotide and 
the RNA nanoparticle. 
8 
In embodiments, the subject has or is at risk of having a 
pathological condition. In embodiments, the subject has 
been diagnosed with a pathological condition. In embodi-
ments, the pathological condition comprises cancer, human 
5 immunodeficiency virus (HIV), influenza, drug and sub-
stance abuse, or a combination thereof. 
Embodiments as described herein comprise a method of 
inducing the production of cytokines. In embodiments, the 
method comprises administering to the subject an effective 
10 amount of an embodiment as described herein. In embodi-
ments, the inducing the production of cytokines is increased 
at least about one fold, about two fold, about three fold, 
about four fold, about five fold, about six fold, about seven 
In embodiments, the RNA-oligonucleotide and immuno- 15 
stimulatory motif are incorporated into the RNA nanopar-
ticle by the RNA-oligonucleotide being covalently bonded 
fold, about eight fold, about nine fold, about ten fold, about 
fifteen fold, about twenty fold, about thirty fold, about forty 
fold, about fifty fold as compared to the adjuvant, the 
antigen, and/or the targeting ligand provided independently 
of the RNA nanostructure. In embodiments, the cytokines 
comprise TNF-alpha, IL-6, IL-12, or a combination thereof. 
to an RNA strand of the RNA nanoparticle. 
In embodiments, the antigen comprises at least one anti-
gen derived from a bacteria, virus, cell, a combination 20 
thereof, or a portion thereof. 
In embodiments, the subject has or is at risk of having a 
pathological condition. In embodiments, the subject has 
been diagnosed with a pathological condition. In embodi-
ments, the pathological condition comprises cancer, human 
immunodeficiency virus (HIV), influenza, drug and sub-
stance abuse, or a combination thereof. 
In embodiments, the antigen comprises at least one anti-
gen that binds to a neutralizing antibody, an inhibitory 
antibody, a combination thereof, or a portion thereof. 
In embodiments, the antigen comprises at least one neu- 25 
tralizing epitope. Embodiments as described herein comprise a method of 
inducing the production of high affinity neutralizing anti-
bodies or inhibitory antibodies. In embodiments, the method 
comprises administering embodiments as described herein 
In embodiments, the antigen comprises B-cell epitope, 
T-cell epitope, T-helper epitope, epitopes derived from 
PG120, gp41 epitopes, glycans, peptides, T-helperpeptides, 
streptavidin, or a combination thereof. 
In embodiments, the targeting ligand comprises an 
aptamer, a cell surface marker, folate, siRNA, shRNA, or a 
combination thereof. In embodiments, the aptamer binds to 
an HIV epitope. In embodiments, the cell surface marker is 
30 to a subject having a pathological condition. In embodi-
ments, the pathological condition comprises cancer, human 
immunodeficiency virus (HIV), influenza, drug and sub-
stance abuse, or a combination thereof. 
a macrophage or a lymphocyte. In embodiments, the target- 35 
ing ligand targets B cells, T cells, dendritic cells, macro-
phages, and/or cancer cells. 
Embodiments as described herein comprise the use of 
embodiments as described herein for the manufacture of a 
medicament useful for the treatment of a pathological con-
dition in a subject. In embodiments, the pathological con-
dition comprises cancer, human immunodeficiency virus 
(HIV), influenza, drug and substance abuse, or a combina-
Embodiments as described herein comprise one or more 
targeting ligands. Embodiments as described herein com-
prise at least two targeting ligands. In embodiments, the 40 
targeting ligands are the same. In other embodiments, the 
targeting ligands are not all the same. In other embodiments, 
the targeting ligands are different. 
tion thereof. 
Embodiments as described herein comprise a composition 
as described herein for use in the prophylactic or therapeutic 
treatment of a pathological condition. In embodiments, the 
pathological condition comprises cancer, human immuno-Embodiments as described herein induce an immune 
response in a subject. In embodiments, the immune response 
increases cytokines at least about one fold, about two fold, 
about three fold, about four fold, about five fold, about six 
fold, about seven fold, about eight fold, about nine fold, 
about ten fold, about fifteen fold, about twenty fold, about 
thirty fold, about forty fold, about fifty fold as compared to 
the adjuvant, the antigen, and/or the targeting ligand pro-
vided independently of the RNA nanostructure. 
Embodiments as described herein comprise a method of 
inducing an immune response in a subject comprising 
administering to the subject an effective amount of an 
embodiment as described herein. 
Embodiments as described herein comprise a method of 
inducing the production of cytokines comprising adminis-
tering to a subject an effective amount of an embodiment as 
described herein. In embodiments, the inducing the produc-
tion of cytokines is increased at least about one fold, about 
two fold, about three fold, about four fold, about five fold, 
about six fold, about seven fold, about eight fold, about nine 
fold, about ten fold, about fifteen fold, about twenty fold, 
about thirty fold, about forty fold, about fifty fold as com-
pared to the immunostimulatory motif provided indepen-
dently of the RNA-oligonucleotide. 
45 deficiency virus (HIV), influenza, drug and substance abuse, 
or a combination thereof. 
Embodiments as described herein comprise a method of 
making an RNAnanostructure. In embodiments, the method 
comprises mixing a multiple of external RNA strands, and 
50 one internal RNA strand to make a mixture; annealing the 
mixture for one hour in a thermocycler; cooling the mixture 
at about 1 ° C. per minute from about 80° C. to about 4 ° C. 
In embodiments, equimolar concentrations of a multiple of 
external RNA strands, and one internal RNA strand can be 
55 mixed. In embodiments, the mixture can be annealed for 1, 
5, 10, 20, 30, 40, 50, 60, 70, 80, 90 minutes. In embodi-
ments, the mixture can be cooled to 1, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 20, 30, 40, 50, 60, 70° C. In embodiments, the mixture 
can be cooled at about 1, about 2, about 3, about 4, about 5, 
60 about 6, about 7, about 8, about 9, about 10° C. per minute. 
In embodiments, the method can further comprise modify-
ing one or more of the external strands to contain an antigen, 
adjuvant, targeting ligand, or combination thereof. In 
embodiments, the external strands comprise 1, 2, 3, 4, 5, 6, 
65 7, 8, 9, 10 strands. In embodiments, the external strands 
comprise 10, 20, 30, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 
50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 nucleotides. In 
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embodiments, the nanostructure comprises a pRNA 3WJ 
motif at each vertex. In embodiments, the nano structure has 
a shape comprising a triangle, square and pentagon. In 
embodiments, the shape comprises a stretched intrahelical 
angle between Hl and H2. 
Embodiments as described herein can comprise one or 
more of SEQ ID. NO 1, SEQ ID. NO 2, SEQ ID. NO 3, SEQ 
ID. NO 4, SEQ ID. NO 5, SEQ ID. NO 6, SEQ ID. NO 7, 
SEQ ID. NO 8, SEQ ID. NO 9, SEQ ID. NO 10, SEQ ID. 
NO 11, SEQ ID. NO 12, SEQ ID. NO 13, SEQ ID. NO 14, 
SEQ ID. NO 15, SEQ ID. NO 16, SEQ ID. NO 17, SEQ ID. 
NO 18, SEQ ID. NO 19, SEQ ID. NO 20, SEQ ID. NO 21, 
SEQ ID. NO 22, SEQ ID. NO 23, SEQ ID. NO 24, SEQ ID. 
NO 25, SEQ ID. NO 26, SEQ ID. NO 27, SEQ ID. NO 28, 
SEQ ID. NO 29, SEQ ID. NO 30, SEQ ID. NO 31, SEQ ID. 
NO 32, SEQ ID. NO 33, or any combination thereof. In one 
embodiment, the oligonucleotide has at least 60%, at least 
65%, at least 70%, at least 80%, at least 85%, at least 90%, 
10 
FIGS. 4A and 4B shows a comparison of polygon sta-
bilities. (A) Melting temperatures of triangle, square and 
pentagon measured by 7% perpendicular TGGE and (B) 
boiling resistance assay in absence and presence of 8 M 
5 urea. Calculated percentage of recovery for polygons after 
boiling is shown below each gel with error bars calculated 
from several independent experiments. 
FIGS. SA-SD shows the effect of cytokine induction in 
macrophage-like RAW264.7 cells and mice by RNA-CpG 
10 polygons. Induction of (A) TNF-a and (B) IL-6 cytokines by 
50 nM RNA polygons-CpG. (C) Dependences of TNF-a 
induction with the number of CpGs per RNA polygon. The 
error bars represent standard deviation from at least three 
15 independent experiments. (D) Immunostimulatory activity 
by triangle-CpG nanoparticle in animal model. The error 
bars represent standard deviations of two independent mea-
surements of the cytokine levels from serum aliquots of the 
tested mouse. at least 91 %, at least 92%, at least 93%, at least 94%, at least 
95%, at least 96%, at least 97%, at least 98%, at least 99%, 20 
or 100% identity to a nucleic acid sequence comprising SEQ 
FIGS. 6A and 6B shows a comparison of RNA polygon-
CpG complexes binding to the cells. (A) The plot represents 
the summary of the flow cytometry data showing each RNA 
nanoparticle-CpG adjuvants binding to the cell in a dose-
dependent manner. (B) Confocal images showing the bind-
ID Nos 1-33. In one embodiment, the oligonucleotide has at 
least 60%, at least 65%, at least 70%, at least 80%, at least 
85%, at least 90%, at least 91 %, at least 92%, at least 93%, 
at least 94%, at least 95%, at least 96%, at least 97%, at least 
98%, at least 99%, or 100% similarity to a nucleic acid 
sequence comprising SEQ ID Nos 1-33. 
25 ing comparison of the triangle-CpG and CpG to the 
RAW624.7 cells by colocalization of nucleus (blue), actin or 
cytoplasm (green) and Cy-3-labeled CpGs (red) signals. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. 7 A-7D shows RNA polygons dissociation constant 
determination at equilibrium state. These are 7% native 
The new features of embodiments as described herein are 
30 PAGE titration data for formation of triangle (a), square (b), 
and pentagon ( c) polygons. Below, the gels is the plot used 
to determine the equilibrium concentration for each polygon 
which were then used to calculate the apparent dissociation 
constant. 
set forth with particularity in the appended claims. The 
drawings were originally published in color, incorporated by 
reference in their entireties (Emil F. Khisamutdinov, et. al., 
Enhancing immunomodulation on innate immunity by shape 35 
transition among RNA triangle, square and pentagon 
nanovehicles, Nucleic Acids Res. 2014 Sep. 2; 42(15): 
9996-10004.). The black and white drawing of the instant 
application correspond to the color ones published. A better 
understanding of the features and advantages of the present 40 
invention will be obtained by reference to the following 
detailed description that sets forth illustrative embodiments, 
in which the principles of the invention are used, and the 
accompanying drawings of which: 
FIGS. lA and lB shows details of the structural features 45 
of the pRNA 3WJ motif. (A) Secondary structure of 3WJ 
motif with base pairs annotated using Leontis-Westhof 
nomen-clature. Figure discloses SEQ ID NOS 34-36, 
respectively, in order of appearance. (B) Tertiary structure of 
the 3WJ motif with indication of the LAOB-60° angle 50 
formed between Hl and H2. The LAOB Angle corresponds 
to inner angles of polygons. 
FIGS. 2A-2C shows the design of RNA nanostructure 
polygons and assembly properties. (A) 3D modeled struc-
tures of polygons with 3WJ motif located at vertices, inner 55 
angle corresponds to LAOB 60°. (B) The increasing length 
FIGS. SA-SC shows sequences and secondary structures 
of RNA polygons. RNA polygons and quantified assembly 
yields for triangle (a), square (b) and pentagon (c). FIG. SA 
discloses regions ArRrDrRI as SEQ ID NOS 37-40, respec-
tively. FIG. SB discloses regions AsQR-EsQR as SEQ ID 
NOS 41-45, respectively. FIG. SC discloses regions APENr-
F PENT as SEQ ID NOS 46-51, respectively. 
FIG. 9A-9C shows RNA polygons population on mica 
surface AFM images of RNA polygons and population 
distribution of RNA triangle (a), square (b ), and pentagon (c) 
polygons in 0.5 mm2 area of AFM mica surface. Error 
represents counts from several independent images. 
FIGS. lOA and lOB shows secondary structure of tri-
angle-CpG nanoparticle and characterization. (a) 2D struc-
ture of RNA triangle harboring 3 CpG adjuvants. Note: 
Arrows indicate to base pairs that have been deleted in RNA 
triangle nanoparticle use for animal confocal microscope, 
and cytotoxicity studies. (b) This is 4% agarose gel showing 
assembly of RNA triangle nanoscaffold with CpG adjuvants. 
FIG. lOC shows (c) DLS characterization of the triangle-
3CpG complex showing apparent hydrodynamic diameter of 
around 14 nm. The error represents standard deviation from 
several independent measurements. 
FIG. 11 shows the secondary structure of a square-CpG 
nanoparticle and characterization. (a) 2D structure of RNA 
of the internal strand stretches the 3WJ LAOB at which the 
nanoparticles assemble, along with increasing number of 
external 'short' strands. FIG. 2 (C) Assembly properties of 
polygons evaluated on 7% native PAGEs. Asterisks '*' 
indicate the Cy5 labeled strands utilized on each type of 
polygon assembly. 
FIG. 3 shows structural characterization of polygons. (A) 
Atomic Force Microscopy (AFM) images of triangular, 
square and pentagonal nanoparticles derived from the pRNA 
3WJ motif. (B) Polygons size distribution histogram 
obtained via dynamic light scattering. 
60 square harboring 4 CpG adjuvants. Figure discloses regions 
AsQR-EsQR as SEQ ID NOS 59 and 60, 61 and 62, 63 and 
64, 65, and 66, respectively. (b) This is 4% agarose gel 
showing assembly of RNA square nanoscaffold with CpG 
adjuvants. (c) DLS characterization of the square-4CpG 
65 complex showing apparent hydrodynamic diameter of 
around 15 nm. The error represents standard deviation from 
several independent measurements. 
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FIG. 12 shows the secondary structure of a pentagon-CpG 
nanoparticle and characterization. (a) 2D structure of RNA 
pentagon harboring 5 CpG adjuvants. Figure discloses 
regions APENrF PENT as SEQ ID NOS 67 and 68, 69 and 70, 
71 and 72, 73 and 74, 75 and 76, and 77, respectively. (b) 5 
This is 4% agarose gel showing assembly of RNA pentagon 
nanoscaffold with CpG adjuvants. (c) DLS characterization 
of the pentagon-5CpG complex showing apparent hydrody-
namic diameter of around 16 nm. The error represents 
standard deviation from several independent measurements. 10 
FIG. 13 shows the effect of RNA-CpG adjuvants on 
RAW264.7 cell viability. The cells were incubated with 
different concentrations of RNA polygons only, RNA poly-
gons-CpG complexes, and free CpG. 
FIG. 14 shows the binding effect of RNA polygons 15 
harboring CpG adjuvants to RA W264. 7 cells. Concentration 
dependent binding of (a) triangle-3CpGs, (b) square-4CpGs, 
and (c) pentagon-5CpGs nanoparticles. 
FIG. 15 shows the results of a serum stability assay of 
RNA polygons coupled with CpGs motifs. Preassembled 20 
complexes (1 µM) of RNA triangle, square and pentagon 
(2'-F modified) harboring DNA CpG were incubated in 
RPMI-1640 medium containing 10% fetal bovine serum 
(Sigma). Aliquots (10 µL) were taken at Ohr, 1 hr, 3 hr, 6 hr, 
8 hr and 16 hr time points after incubation at 37° C., 25 
followed by analysis using 6% native PAGE gel. 
FIG. 16 shows thermodynamically stable RNA nanopar-
ticles for efficient delivery of immunostimulatory CpG oli-
gonucleotides, RNA or antigen to immune cells, 
12 
harboring RNA triangle. Triangle with 2 CpG ODN can be 
successfully purified and imaged by AFM. The image shows 
that triangle-CpG assemble well and most of the particles 
are shown as triangular shape. Based on the AFM image, the 
diameter of triangle with 3 CpG is around 30 nm, a bit larger 
than the original triangle. 
FIG. 32 shows Dynamic Light Scattering (DLS) data 
showing the mean diameter of triangle-3CpGs of 16.7 nM 
and its agreement with AFM imaging data. 
FIG. 33 shows how the RNA nanostructure triangle 
protects CpG oligonucleotides from degradation in serum 
over time. 
FIG. 34 shows a Temperature Gradient Gel Electropho-
resis (TGGE) ofRNAnanostructure triangle harboring CpG 
oligonucleotides over increasing temperatures from 30° C. 
to 80° C. 
FIG. 35 shows a chart of relative cell viability vs. con-
centration from investigation of toxicity of RNA Triangle-
CpG. 
FIG. 36 shows a flowcytometry study of 300 nM triangle 
RNA harboring different numbers of CpGs binding to raw 
264.7 cells. Positive binding: Triangle-lCpG 300 nM-Tri-
angle-2CpGs 300 nM=Triangle-3Cpgs 300 nM>CpG 300 
nM. 
FIG. 37 shows a flowcytometry study of 1500 nM triangle 
RNA harboring different numbers of CpGs binding to raw 
264.7 cells. Positive binding: Triangle-lCpG 150 
nM=Triangle 2CpGs 15-nM=Triangle-3CpGs 150 nM>CpG 
150 nM. FIG. 17 shows RNA and DNA sequence for triangle- 30 
3CpGs (SEQ ID NOS 78-85, 17, 19, and 21, respectively, in 
order of appearance) FIG. 38 shows a flowcytometry study of 75 nM triangle RNA harboring different numbers of CpGs binding to raw 
264.7 cells. Positive binding: Triangle-lCpG 75 
35 nM=Triangle-2CpGs 75 nM=Triangle-3CpGs 75 nM>CpG 
75 nM. 
FIG. 18 shows CpG only, a nanostructure RNA triangle 
only, and a RNA nano structure triangle with optionally one, 
two and three CpGs. 
FIG. 19 shows thermodynamically stable RNA three-way 
junction (3WJ) for efficient delivery of immunostimulatory 
CpG oligonucleotides, RNA or antigen to immune cells. 
Figure discloses SEQ ID NOS 86-88, respectively, in order 
of appearance. 
FIG. 20 shows a bowtie-like RNA nanoparticle triangle 
dimer for delivery of 4CpG. The size of the nanoparticle is 
twice as triangle (about 20 nmx15 nm). 
FIG. 39 shows a flowcytometry study of37.5 nM triangle 
RNA harboring different numbers of CpGs binding to raw 
264.7 cells. Positive binding: Triangle-lCpG 37.5 
40 nM=Triangle 2CpGs 37.5 nM=Triangle-3CpGs 37.5 
nM>CpG 37.5 nM. 
FIG. 40 shows a flowcytometry studying different con-
centration of triangle-lCpG binding to raw 264.7 cells. 
FIG. 21 shows RNA triangle, square and pentagon nano-
particles harboring different numbers of CpGs and Cy3- 45 
labeled DNAs 
Positive binding: Triangle-lCpG 300 nM>Triangle-lCpG 
150 nM>Triangle-lCpG 75 nM>Triangle-lCpG 37.5 nM. 
FIG. 41 shows a flowcytometry studying different con-
centration of triangle-2CpGs binding to raw 264.7 cells. 
Positive binding: Triangle-2CpG 300 nM>Triangle-2CpG 
150 nM>Triangle-2CpG 75 nM>Triangle-2CpG 37.5 nM. 
FIG. 22 shows an RNA nanoparticle for anticancer vac-
cine or immunotherapy 
FIG. 23 shows a 3WJ nanovaccine containing CpG-ODN 
adjuvant and antitumor antigen and a 4WJ nanovaccine 50 
containing CpG-ODN adjuvant and antitumor antigen 
FIG. 24 shows a Triangle RNA nanostructure harboring 
CpG-G ODN and siRNA. 
FIG. 42 shows a flowcytometry studying different con-
centration of triangle-3CpGs binding to raw 264.7 cells. 
Positive binding: Triangle-3CpG 300 nM>Triangle-3CpG 
150 nM>Triangle-3CpG 75 nM>Triangle-3CpG 37.5 nM. 
FIG. 25 shows the assemblies of RNA nanostructure 
triangles harboring CpG oligonucleotides. 
FIG. 26 shows AFM images of RNA nanostructure tri-
angles harboring three CpGs. 
FIG. 43 shows a flowcytometry studying different con-
55 centration of CpG binding to raw 264.7 cells. Positive 
binding: CpG 300 nM>CpG 150 nM>CpG 75 nM>CpG 
37.5 nM. 
FIG. 27 shows AFM images of RNA nanostructure tri-
angles harboring three CpGs. 
FIG. 28 shows AFM images of RNA nanostructure tri- 60 
angles harboring three CpGs. 
FIG. 29 shows AFM images of RNA nanostructure tri-
angles harboring three CpGs. 
FIG. 44 shows a table showing differing concentrations of 
CpG, Triangle-lCpG, Triangle-2CpGs, and Triangle-3CpGs 
and their respective levels of binding. Triangle-lCpG, Tri-
angle-2CpGs and Triangle-3CpGs all have much stronger 
binding than CpG only. Triangle should enhance the delivery 
of CpG, which is also in agreement with the previous 
cytokine data (stronger binding correlates to stronger FIG. 30 shows AFM images of RNA nanostructure tri-
angles harboring three CpGs. 65 cytokine induction). 
FIG. 31 shows detailed AFM images of RNA nanostruc-
ture triangles harboring three CpGs and a scheme of the CpG 
FIG. 45 shows a flowcytometry comparing square RNA 
harboring different number of CpGs binding to raw 264.7 
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cells. Positive binding: Square-I CpG=Square-2CpGs-
1 =Square-2CpGs-2=Square-3CpGs=Square-4CpGs>CpG 
Only 
FIG. 46 shows a flowcytometry comparing pentagon 
RNA harboring different number of CpGs binding to raw 5 
264.7 cells. Positive binding: Pentagon-5CpG=Pentagon-
4CpG=Pentagon-3CpGs-l =Pentagon-3CpGs-2=Pentagon-
2CpGs- l =Pentagon-2CpGs-2>Pentagon-1 CpG>CpG only. 
FIG. 47 shows a flowcytometry comparing triangle-
3CpG, square-4CpG, and pentagon-5CpG RNA nanostruc- 10 
tures binding to raw 264.7 cells. Positive binding: Pentagon-
5CpG=Square-4CpG=Triangle-3CpG>CpG only. 
FIG. 48 shows confocal imaging of triangle-CpG inter-
acting with raw cells. 
FIG. 49 shows confocal imaging of triangle-CpG inter- 15 
acting with raw cells. 
FIG. 50 shows fluorescent imaging of morphology 
changes oftriangle-CpG induced raw cells. Upon treatment 
with triangle-CpG or CpG, the cell morphology changed 
from a round form to an elongated form with more spreading 20 
and forming pseudopodia. 
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SEQ ID NO 3 is an exemplary RNA sequence for Triangle 
short strand C used in assembly of an RNA triangle nano-
structure. 
SEQ ID NO 4 is an exemplary RNA sequence for Triangle 
long strand D used in assembly of an RNA triangle nano-
structure. 
SEQ ID NO 5 is an exemplary RNA sequence for Square 
short strand A used in assembly of an RNA square nano-
structure. 
SEQ ID NO 6 is an exemplary RNA sequence for Square 
short strand B used in assembly of an RNA square nano-
structure. 
SEQ ID NO 7 is an exemplary RNA sequence for Square 
short strand C used in assembly of an RNA square nano-
structure. 
SEQ ID NO 8 is an exemplary RNA sequence for Square 
short strand D used in assembly of an RNA square nano-
structure. 
SEQ ID NO 9 is an exemplary RNA sequence for Square 
long strand E used in assembly of an RNA square nano-
structure. 
SEQ ID NO 10 is an exemplary RNA sequence for 
pentagon short strand A used in assembly of an RNA 
pentagon nanostructure. 
FIG. 51 shows results of TNF-alpha cytokine ELISA 
assay for 1) Triangle-CpG compared to Triangle RNA, CpG, 
cell only, and blank medium and 2) increasing concentration 
of Triangle-CpG. 
FIG. 52 shows IL-6 cytokine ELISA assay for 1) Triangle-
CpG compared to Triangle RNA, CpG, cell only, and blank 
medium and 2) increasing concentration of Triangle-CpG. 
SEQ ID NO 11 is an exemplary RNA sequence for 
25 pentagon short strand B used in assembly of an RNA 
pentagon nanostructure. 
FIG. 53 shows a chart comparing TNF-alpha cytokine 
ELISA assay for RNA triangles harboring different numbers 30 
ofCpG. 
FIG. 54 shows a chart comparing TNF-alpha cytokine 
ELISA assay for RNA squares harboring different numbers 
ofCpG. 
FIG. 55 shows a chart comparing TNF-alpha cytokine 35 
ELISA assay for RNA pentagons harboring different num-
bers ofCpG. 
FIG. 56 shows a schematic showing self-assembly of 
RNA triangle nanostructure harboring CpG RNAs, and the 
CpG RNA sequences with 21 nucleotide overhang and 5U 40 
linker. 
FIG. 57 shows the sequence of A21 CpGRNA, the 63 
nucleotide DNA, the 5' Primer and the 3' Primer. 
SEQ ID NO 12 is an exemplary RNA sequence for 
pentagon short strand C used in assembly of an RNA 
pentagon nanostructure. 
SEQ ID NO 13 is an exemplary RNA sequence for 
pentagon short strand D used in assembly of an RNA 
pentagon nanostructure. 
SEQ ID NO 14 is an exemplary RNA sequence for 
pentagon short strand E used in assembly of an RNA 
pentagon nanostructure. 
SEQ ID NO 15 is an exemplary RNA sequence for 
pentagon long strand F used in assembly of an RNA 
pentagon nanostructure. 
SEQ ID NO 16 is an exemplary strand A21 CpG RNA. 
SEQ ID NO 17 is an exemplary strand A21 CpG DNA. 
SEQ ID NO 18 is an exemplary strand B21 CpG RNA. 
SEQ ID NO 19 is an exemplary strand B21 CpG DNA. 
SEQ ID NO 20 is an exemplary strand C21 CpG RNA. 
SEQ ID NO 21 is an exemplary strand C21 CpG DNA. 
SEQ ID NO 22 is an exemplary RNA sequence Tri A-Cpg FIG. 58 shows the sequence of B21 CpGRNA, the 63 
nucleotide DNA, the 5' Primer and the 3' Primer. 45 for assembly of RNA Triangle harboring RNA CpG motif. 
FIG. 59 shows the sequence of C21 CpGRNA, the 63 
nucleotide DNA, the 5' Primer and the 3' Primer. 
FIG. 60 shows the PCR of the DNA templates for A21, 
B21 and C21 CpG RNA. 
SEQ ID NO 23 is an exemplary RNA sequence Tri B-CpG 
for assembly of RNA Triangle harboring RNA CpG motif. 
SEQ ID NO 24 is an exemplary RNA sequence Tri C-CpG 
for assembly of RNA Triangle harboring RNA CpG motif. 
FIG. 61 shows the image of 2'F CpG RNA made by in 50 SEQ ID NO: 25 is a 63 nucleotide DNA sequence 
including the sequence of SEQ ID NO: 17, and SEQ ID NO: 
26 and SEQ ID NO: 27 are 5'- and 3'-primers, as set forth in 
FIG. 57. 
vitro transcription. 
FIG. 62 shows a summary of data of the cytokine testing 
of 2'F RNA triangle harboring DNA CpG, DNA triangle 
harboring DNA CpG, and 2'F RNA triangle harboring 2'F 
RNACpG. 
FIG. 63 shows the design of an RNA Nanostructure 
Triangle with RNA CpG motif. Figure discloses SEQ ID 
NOS 89-93, respectively, in order of appearance. 
DESCRIPTION OF THE SEQUENCE LISTING 
SEQ ID NO 1 is an exemplary RNA sequence for Triangle 
short strand A used in assembly of an RNA triangle nano-
structure. 
SEQ ID NO: 28 is a 63 nucleotide DNA sequence 
55 including the sequence of SEQ ID NO: 19, and SEQ ID NO: 
29 and SEQ ID NO: 30 are 5'- and 3'-primers, as set forth in 
FIG. 58. 
SEQ ID NO: 31 is a 63 nucleotide DNA sequence 
including the sequence of SEQ ID NO: 21, and SEQ ID NO: 
60 32 and SEQ ID NO: 33 are 5'- and 3'-primers, as set forth in 
FIG. 59. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
SEQ ID NO 2 is an exemplary RNA sequence for Triangle 65 
short strand B used in assembly of an RNA triangle nano-
structure. 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
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Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. In case of conflict, the specification of 
this document, including definitions, will control. 
In certain instances, nucleotides and polypeptides dis-
closed herein are included in publicly-available databases, 
such as GENBANK® and SWISSPROT. Information 
including sequences and other information related to such 
nucleotides and polypeptides included in such publicly-
available databases are expressly incorporated by reference. 
Unless otherwise indicated or apparent the references to 
such publicly-available databases are references to the most 
recent version of the database as of the filing date of this 
Application. 
While the terms used herein are believed to be well 
understood by one of ordinary skill in the art, definitions are 
set forth to facilitate explanation of the presently-disclosed 
subject matter. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a cell" comprises a plurality of such cells, and so 
forth. 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
As used herein, the term "about" can encompass varia-
tions of in some embodiments ±20%, in some embodiments 
±10%, in some embodiments ±5%, in some embodiments 
±1%, in some embodiments ±0.5%, and in some embodi-
ments ±0.1 % from the specified amount, as such variations 
are appropriate to perform the disclosed method. For 
example, the term "about" can refer to a value or an amount 
of mass, weight, time, volume, concentration, percentage, 
number, or temperature. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
As used herein, the term "sequence identity", "sequence 
similarity" or "homology" is used to describe sequence 
relationships between two or more nucleotide sequences. 
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The percentage of "sequence identity" between two 
sequences is determined by comparing two optimally 
aligned sequences over a comparison window, wherein the 
portion of the sequence in the comparison window may 
5 comprise additions or deletions (i.e., gaps) as compared to 
the reference sequence (which does not comprise additions 
or deletions) for optimal alignment of the two sequences. 
The percentage is calculated by determining the number of 
positions at which the identical nucleic acid base or amino 
10 acid residue occurs in both sequences to yield the number of 
matched positions, dividing the number of matched posi-
tions by the total number of positions in the window of 
comparison, and multiplying the result by 100 to yield the 
percentage of sequence identity. A sequence that is identical 
15 at every position in comparison to a reference sequence is 
said to be identical to the reference sequence and vice-versa. 
As used herein, "Adjuvant" refers to a composition, 
chemical or biological agent given in combination with a 
composition, an antibody, polynucleotide or polypeptide to 
20 enhance its immunogenicity. 
The area of biomimetic nanotechnology involves the 
construction of nano-scale, supramolecular architectures uti-
lizing modular units of functional nucleic acids. The aim is 
to design nanostructures that undergo self-assembly in con-
25 trollable and recyclable fashion. Ribonucleic acid (RNA) 
was discovered as an attractive material to build nanopar-
ticles via nanotechnology (1 ), offering a variety of structural 
modules and motifs that can be manipulated into 1 D, 2D and 
3D architectures (for review see (2)). In the past decade, a 
30 variety of geometric RNA nanoparticles and nano-scaffolds 
have been obtained via the approaches of hand-in-hand 
(1,3-5), foot-to-foot (6-9), branch extension (10-14), loop-
receptor contact (15-17), 'sticky' or 'dangling' ends (6, 18, 
19) and synthetic RNA-protein complex interactions (20). 
35 These motifs are available in data bases and can be used to 
build artificial nanostructures by manipulating their inter-
changeable units (21). Recently, RNA rolling cycle tran-
scription has been utilized to generate RNA sponges (22,23). 
In RNA tectonics approach, structural motifs like double 
40 helices, loops and junctions can be isolated from large and 
complex RNA molecules appearing in structural data bases 
and used to build artificial nanostructures by manipulating 
their interchangeable units (24,25). As such, previously 
reported designs of RNA nanoparticles, e.g. tecto-square 
45 (26), square-shaped nano-scaffolds (27,28), RNA nano-rings 
(1, 5, 7, 9) or pRNA dimers, tetramers and hexamers (1, 7, 
9, 29, 30), as well as RNA nano-cubes (19), RNA polyhe-
dron (14), RNA bundles (6,31) and filaments (15,16) utilize 
fundamental principles of RNA structure and folding (32-
50 36). Overall stability of conventional constructs though, 
mainly relies on the stability of canonical and non-canonical 
base pair (bp) forming by loop-loop, receptor-loop, or 
'sticky-ends' with a number of pairing nucleotides usually 
not exceeding six. A new approach is needed to increase 
55 overall stability of RNA nanoparticles, one that uses natu-
rally-selected stable RNA building blocks for structure 
building, and the example is the 3WJ motif from pRNA of 
bacteriophage phi29 DNA packaging motorional nucleic 
acids. The aim is to design nanostructures that undergo 
60 self-assembly in controllable and recyclable fashion. A new 
approach is needed to increase overall stability of RNA 
nanoparticles, one that uses naturally-selected stable RNA 
building blocks for structure building. An example is the 
3WJ motif from pRNA of bacteriophage phi29 DNA pack-
65 aging motor. In addition to discovering that the pRNA-3WJ 
shows exceptional stability under physiological conditions 
and in the presence of strong denaturing agent (10,11), 
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recent studies also suggest that the thermodynamic stability 
of the 3WJ is entropy driven (37). Stable RNA polygons 
have the potential to serve as a new generation of delivery 
systems for immunomodulators. 
Embodiments as described herein comprise compositions 5 
and adjuvants useful for prophylactic and therapeutic treat-
ment. For example, embodiments comprise immunostimu-
latory RNA-containing compositions and RNA nanopar-
ticle-containing compositions. The compositions described 
herein are safe, effective, versatile, and easy to manufacture, 10 
offering new solutions to address unmet needs associated 
with current approaches to vaccine design and development. 
RNA can be used as a construction material, immunos-
timulatory agent, or a combination thereof for the develop- 15 
ment of new nanovaccines and adjuvants for disease pre-
vention and treatment. 
Ultrastable RNA nanoparticles comprising RNA, CpG 
DNA, peptide antigen or protein antigen can be pre-de-
signed in silica and fabricated by thermodynamically-driven 20 
self-assembly. The fabricated RNA nanoparticle-based 
nanovaccine and adjuvants have pre-defined stoichiometry, 
size and structure, and are also thermodynamically ultrast-
able and resistant to degradation in serum. The cellular 
uptake of the RNA nanoparticle-based nanovaccine and 25 
adjuvants is greatly enhanced compared to CpG DNA only 
and antigen only. The immune response induced by the RNA 
nanoparticle-based nanovaccine and adjuvants will also be 
greatly enhanced compared to CpG DNA only and antigen 
only. The RNA nanoparticle-based nanovaccines and adju- 30 
vants could also be conjugated to a variety of targeting 
ligands for targeting to B cells, T cells, dendritic cells, 
macrophages, cancer cells, or a combination thereof. The 
targeting ligands comprises but are not limited to folate, 
RNA aptamers, DNA aptamers, or a combination thereof. In 35 
certain embodiments, multiple targeting ligands can be 
conjugated to one nanoparticle to enhance the targeting 
efficacy. 
ssRNA, dsRNA and siRNA have been shown to have 
immunostimulatory activities. Embodiments as described 40 
herein comprise an immunostimulatory agent comprising 
chemically modified RNA. The chemically modified RNA 
comprises immunostimulatory motifs which comprises, but 
are not limited to, the CpG motif. Embodiments as described 
herein further comprise vaccine and adjuvant platforms that 45 
use the immunostimulatory RNA as one of the platform 
components. Moreover, the immunostimulatory RNA can 
also be incorporated into ultrastable RNA nanoparticles 
comprising RNA, CpG DNA, peptide antigen or protein 
antigen to form nanovaccines. The fabricated RNA nano- 50 
particle-based nanovaccine and adjuvants have pre-defined 
stoichiometry, size and structure, and are also thermody-
namically ultrastable and resistant to degradation in serum. 
The immune response induced by the immunostimulatory 
RNA platform will be greatly enhanced compared to CpG 55 
DNA only and antigen only. The immunostimulatory RNA 
platform could also be conjugated to a variety of targeting 
ligands for targeting to B cells, T cells, dendritic cells, 
macrophages, cancer cells, or a combination thereof. The 
targeting ligands comprise but are not limited to folate, 60 
siRNA, shRNA, RNA aptamers, DNA aptamers, or a com-
bination thereof. In certain embodiments, multiple targeting 
ligands can be conjugated to one platform to enhance the 
targeting efficacy. The vaccine platform according to the 
invention and the adjuvants platform according to the inven- 65 
tion are employed to treat or prevent various diseases 
comprising, but not limited to, cancer, immunology, respi-
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ratory, central nervous system, inflanimatory, cardiovascu-
lar, infectious diseases, drug and substance abuse, or a 
combination thereof. 
RNA-based compositions disclosed herein, including 
RNA-nanoparticle-containing and RNA-oligonucleotide-
containing compositions, have a number of advantageous 
features. Such advantages comprises the following. The 
RNA-based compositions have defined size, structure and 
stoichiometry, such that unpredictable side effects arising 
from heterogeneous particles can be avoided. Due to the 
multivalent nature of RNA nanoparticles, multiple antigen 
and adjuvants could be incorporated into one particle for 
achieving synergistic or enhanced immune repose such as 
cytokine induction and antibody production. The nanosize 
of the particles will facilitate tissue penetration and target to 
important immune tissues or organs such as lymph nodes for 
achieving targeted and enhanced immune stimulation. Mul-
tiple targeting ligands could be incorporated into one par-
ticle for achieving better targeting to immune cells such as 
B cells, T cells, dendritic cells and macrophages. Economic 
and easy fabrication of RNA-based compositions could be 
performed in a cell-free system which allows for industrial 
scale production and avoids possible contamination. RNA 
nanoparticles are highly soluble and not prone to aggrega-
tion. They do not require any addition steps, such as linkage 
to PEG to keep them stable in solution. RNA nanoparticles 
are also thermodynamically stable. For example, the trian-
gular shaped RNAnanoparticles are resistant to boiling. The 
three-way junction RNA nanoparticles are resistant to SM 
urea denaturation. Thus RNA nanoparticles will remain 
intact and not disassociate at ultra-low concentrations in 
vivo. 2'F-modified RNA-based compositions, for example, 
are resistant to degradation in serum and stable in the blood. 
The cellular uptake of the RNA nanoparticle-based nano-
vaccine and adjuvants is greatly enhanced compared to CpG 
DNA only and antigen only. The immunostimulatory activ-
ity of the chemical modified RNA-based compositions dis-
closed herein is stronger than other adjuvants such as CpG 
DNA. Due to the larger size of RNA nanoparticle-based 
nanovaccine and adjuvants compared to antigen and adju-
vants only, the in vivo half-life of RNA nanoparticle-based 
nanovaccine and adjuvants is significantly prolonged, offer-
ing better pharmacokinetics profiles and better patient com-
pliance. The immunostimulatory RNA can also be incorpo-
rated into ultrastable RNAnanoparticles composed of RNA, 
CpG DNA, peptide antigen or protein antigen to form 
nanovaccine. The fabricated RNA nanoparticle-based nano-
vaccine and adjuvants have pre-defined stoichiometry, size 
and structure, and are also thermodynamically ultrastable 
and resistant to degradation in serum. The immune response 
induced by the immunostimulatory RNA platform will be 
greatly enhanced compared to CpG DNA only and antigen 
only. RNA-based compositions as described herein are ultra-
stable and resistant to degradation in serum, and can be 
conjugated to ligands to target, for example, B, T, dendritic, 
macrophage, cancer cells, or a combination thereof. 
The presently-disclosed subject matter comprises a com-
position comprising an RNA-oligonucleotide and an immu-
nostimulatory motif. 
In some embodiments, the RNA-oligonucleotide com-
prises a chemical modification, examples of which comprise 
2'Fluoro, 2'Amine, and 2'O-Methyl. In some embodiments, 
the RNA-oligonucleotide comprises about 5, about 6, about 
7, about 8, about 9, about 10, about 11, about 12, about 13, 
about 14, about 15, about 16, about 17, about 18, about 19, 
about 20, about 21, about 22, about 23, about 24, about 25, 
about 26, about 27, about 28, about 29, about 30, about 31, 
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about 32, about 33, about 34, about 35, about 36, about 37, 
about 38, about 39, about 40, about 41, about 42, about 43, 
about 44, about 45, about 46, about 47, about 48, about 49, 
or about 50 bases in length. In some embodiments, the 
RNA-oligonucleotide comprises at least one single-stranded 
RNA oligonucleotide. In other embodiments, the RNA-
oligonucleotide comprises at least one double-stranded or 
partially double-stranded (e.g., containing a hair-pin) RNA 
oligonucleotide. 
In some embodiments, the immunostimulatory motif 
comprises an immunostimulatory RNA (isRNA) and a CpG 
oligodeoxyribonucleotide (CpG). The isRNA can be any 
isRNA known to the skilled artisan, examples of which are 
set forth in Patent Application Publication Nos. US 2014/ 
0135487 and WO 2003/086280, which are incorporated by 
reference in their entireties. In some embodiments, the 
immunostimulatory motif is conjugated to the RNA-oligo-
nucleotide. In some embodiments, the immunostimulatory 
motif is CpG conjugated to the RNA-oligonucleotide. 
In some embodiments, the composition comprising an 
RNA-oligonucleotide and an immunostimulatory motif is 
provided as an adjuvant. In some embodiments, the immune 
modulation effect for cytokine induction is increased at least 
about ten fold as compared to the immunostimulatory motif 
provided independently of the RNA-oligonucleotide. In 
some embodiments, the immune modulation effect for 
cytokine induction is increased at least about two fold, three 
fold, four fold, five fold, six fold, seven fold, eight fold, nine 
fold, fifteen fold, twenty fold, thirty fold, forty fold, fifty fold 
as compared to the immunostimulatory motif provided inde-
pendently of the RNA-oligonucleotide. In some embodi-
ments when immunostimulatory motif is conjugated to the 
RNA-oligonucleotide, the immune modulation effect for 
cytokine induction and cell binding is enhanced at least 10, 
at least 20, at least 30, at least 40, at least 50, at least 7 5, at 
least 100, at least 150, or at least 200 times. 
Embodiments as described herein comprise a composition 
comprising an RNA nanostructure, and an adjuvant, an 
antigen, and/or a targeting ligand. Examples of RNA nano-
structures comprise RNA triangle, RNA square, RNA pen-
tagon, RNA hexagon, RNA three-way junction, RNA four-
way junction 
In some embodiments, the RNA nanostructure comprise 
an RNA triangle, RNA square, RNA pentagon, RNA hexa-
gon, RNA three-way junction, RNA four-way junction. In 
some embodiments, the RNA nano structure is derived from 
a 3WJ motif. A non-limiting example of the RNA nano-
structure comprises an RNA nanostructure that is derived 
from the 3WJ motif, such as that described in the Examples 
herein. Other RNA nanostructures are known to those 
skilled in the art, for example that which is found in 
International Patent Application Publication No. WO 2012/ 
170372, which is incorporated by reference in its entirety. 
In embodiments as described herein, the adjuvant com-
prises an immunostimulatory RNA (isRNA), a CpG oligode-
oxyribonucleotide (CpG), or a combination thereof. In some 
embodiments, the isRNA, can be about 5, about 6, about 7, 
about 8, about 9, about 10, about 11, about 12, about 13, 
about 14, about 15, about 16, about 17, about 18, about 19, 
about 20, about 21, about 22, about 23, about 24, about 25, 
about 26, about 27, about 28, about 29, about 30, about 31, 
about 32, about 33, about 34, or about 35 bases in length. In 
some embodiments the isRNA is about 8 to about 30 bases 
in length. In some embodiments, the adjuvant comprises 
isRNA and the isRNA is incorporated into the RNA nano-
particle by base pairing. In some embodiments, the adjuvant 
comprises isRNA and the isRNA is incorporated into the 
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RNA nanoparticle by being covalently bonded to an RNA 
strand of the RNA nanoparticle. In some embodiments, the 
adjuvant comprises a composition as described herein, an 
example of which comprises an RNA-oligonucleotide and 
5 an immunostimulatory motif. In some embodiments, the 
RNA-oligonucleotide and immunostimulatory motif are 
incorporated into the RNA nanoparticle by base pairing 
between the RNA-oligonucleotide and the RNA nanopar-
ticle. In some embodiments, the RNA-oligonucleotide and 
10 immunostimulatory motif are incorporated into the RNA 
nanoparticle by the RNA-oligonucleotide being covalently 
bonded to an RNA strand of the RNA nanoparticle. 
Embodiments as described here comprise an antigen, 
non-limiting examples of which can be derived from a 
15 bacteria, virus, or cell. In some embodiments, the antigen 
binds to a neutralizing antibody or an inhibitory antibody. In 
some embodiments, the antigen comprises a neutralizing 
epitope. In some embodiments, the antigen comprises a 
B-cell epitope, T-cell epitope, T-helper epitope, epitopes 
20 derived from PG120, gp41 epitopes, glycans, peptides, 
T-helper peptides, streptavidin, or combination thereof. 
Embodiments as described herein comprise a targeting 
ligand, non-limiting examples of which comprise an 
aptamer, a cell surface marker, a cancer cell, or a combina-
25 tion thereof. In some embodiments, where the targeting 
ligand comprises an aptamer, the aptamer can bind to at least 
one HIV epitope. In some embodiments, where the targeting 
ligand comprises a cell surface marker, the cell surface 
marker comprises a macrophage or a lymphocyte. In some 
30 embodiments, the composition comprises at least two tar-
geting ligands. In some embodiments, the composition com-
prises one, two, three, four, five, six, seven, eight, nine, or 
ten targeting ligands. In some embodiments the multiple 
targeting ligands are the same. In other embodiments, the 
35 targeting ligands are different. In some embodiments, not all 
of the multiple targeting ligands are the same. 
As will be appreciated by the skilled artisan, compositions 
disclosed herein can be formulated to comprises a pharma-
ceutically-acceptable carrier. As used herein, the term "phar-
40 maceutically acceptable carrier" refers to sterile aqueous or 
nonaqueous solutions, dispersions, suspensions or emul-
sions, as well as sterile powders for reconstitution into sterile 
injectable solutions or dispersions just prior to use. 
Examples of suitable aqueous and nonaqueous carriers, 
45 diluents, solvents or vehicles comprises water, ethanol, 
polyols (such as glycerol, propylene glycol, polyethylene 
glycol and the like), carboxymethylcellulose and suitable 
mixtures thereof, vegetable oils (such as olive oil) and 
injectable organic esters such as ethyl oleate. Proper fluidity 
50 can be maintained, for example, by the use of coating 
materials such as lecithin, by the maintenance of the 
required particle size in the case of dispersions and by the 
use of surfactants. These compositions can also contain 
adjuvants such as preservatives, wetting agents, emulsifying 
55 agents and dispersing agents. Prevention of the action of 
microorganisms can be ensured by the inclusion of various 
antibacterial and antifungal agents such as paraben, chlo-
robutanol, phenol, sorbic acid and the like. It can also be 
desirable to include isotonic agents such as sugars, sodium 
60 chloride and the like. Prolonged absorption of the injectable 
pharmaceutical form can be brought about by the inclusion 
of agents, such as aluminum monostearate and gelatin, 
which delay absorption. Injectable depot forms are made by 
forming microencapsule matrices of the drug in biodegrad-
65 able polymers such as polylactide-polyglycolide, poly(or-
thoesters) and poly(anhydrides). Depending upon the ratio 
of drug to polymer and the nature of the particular polymer 
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employed, the rate of drug release can be controlled. Depot 
injectable formulations are also prepared by entrapping the 
drug in liposomes or microemulsions which are compatible 
with body tissues. The injectable formulations can be ster-
ilized, for example, by filtration through a bacterial-retaining 5 
filter or by incorporating sterilizing agents in the form of 
sterile solid compositions which can be dissolved or dis-
persed in sterile water or other sterile injectable media just 
prior to use. Suitable inert carriers can comprise sugars such 
as lactose. Desirably, at least 95% by weight of the particles 10 
of the active ingredient have an effective particle size in the 
range of 0.01 to 10 micrometers. 
The presently-disclosed subject matter further comprises 
methods as disclosed herein. For example, a method of 
inducing an immune response in a subject comprises admin- 15 
istering to the subject an effective amount of a composition 
as described herein. In some embodiments, the subject has 
or is at risk of having a pathological condition. Embodi-
ments as described herein further comprises a method of 
inducing the production of cytokines comprising adminis- 20 
tering to a subject an effective amount of a composition as 
described herein. In some embodiments, the cytokines com-
prise TNF-alpha, IL-6, IL-12, or a combination thereof. The 
presently-disclosed subject matter further comprises a 
method of inducing the production of high affinity neutral- 25 
izing antibodies or inhibitory antibodies comprising admin-
istering a composition as described herein to a subject 
having a pathological condition. Exemplary pathological 
conditions comprises, but are not limited to, cancer, immu-
nology, respiratory, central nervous system, inflanmiatory, 30 
cardiovascular, infectious diseases, influenza, human immu-
nodeficiency virus (HIV), and drug and substance abuse, 
such as cocaine or nicotine abuse. 
As used herein, the term "subject" refers to a target of 
administration. The subject of the herein described methods 35 
can be a vertebrate, such as a manmial, a fish, a bird, a 
reptile, or an amphibian. Thus, the subject of the herein 
described methods can be a human or non-human. Thus, 
veterinary therapeutic uses are provided in accordance with 
the presently described subject matter. As such, the presently 40 
described subject matter provides for administration to 
mammals such as humans and non-human primates, as well 
as those mammals of importance due to being endangered, 
such as Siberian tigers; of economic importance, such as 
animals raised on farms for consumption by humans; and/or 45 
animals of social importance to humans, such as animals 
kept as pets or in zoos. Examples of such animals comprise 
but are not limited to carnivores such as cats and dogs; 
swine, including pigs, hogs, and wild boars; ruminants 
and/or ungulates such as cattle, oxen, sheep, giraffes, deer, 50 
goats, bison, and camels; rabbits, guinea pigs, and rodents. 
Also provided is the treatment of birds, including the treat-
ment of those kinds of birds that are endangered and/or kept 
in zoos, as well as fowl, and more particularly domesticated 
fowl, i.e., poultry, such as turkeys, chickens, ducks, geese, 55 
guinea fowl, and the like, as they are also of economic 
importance to humans. Thus, also provided is the treatment 
of livestock, including, but not limited to, domesticated 
swine, ruminants, ungulates, horses (including race horses), 
poultry, and the like. The term does not denote a particular 60 
age or sex. 
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EXAMPLES 
Modulation of immune response is important in cancer 
immunotherapy, vaccine adjuvant development and inflam-
matory or immune disease therapy. Here we report the 
development of new immunomodulators via control of 
shape transition among RNA triangle, square and pentagon 
nanostructures. Changing one RNA strand in polygons auto-
matically induced the stretching of the interior angle from 
60° to 90° or 108°, resulting in self-assembly of elegant 
RNA triangles, squares and pentagons. When immunologi-
cal adjuvants were incorporated, their immunomodulation 
effect for cytokine TNF-a and IL-6 induction was greatly 
enhanced in vitro and in animals up to 100-fold, while RNA 
polygon controls induced unnoticeable effect. The RNA 
nanoparticles were delivered to macrophages specifically. 
The degree of immunostimulation greatly depended on the 
size, shape and number of the payload per nanoparticles. 
Stronger immune response was observed when the number 
of adjuvants per polygon was increased, demonstrating the 
advantage of shape transition from triangle to pentagon. 
By stretching the 60° AOB angle (L) (FIG. 1) of the 
thermodynamically stable pRNA 3WJ motif, stable RNA 
architectures can be designed. We demonstrate that it can be 
stretched to wide conformations resulting in different 2D 
polygons: triangle (LAOB=) 60°, square (LAOB=90°) and 
pentagon (LAOB=108°). Intermolecular interactions such 
as kissing loops, receptor loop, or 'sticky-ends' were 
avoided by introducing linkages through base pairing 
between corners of the polygons using RNA double helices. 
Therefore, this system is advantageous with an increased 
thermo-stability in the overall construct. 
We further demonstrate that the RNA polygons have the 
potential to serve as a new generation of delivery systems for 
immunomodulators. Synthetic unmethylated cytosine-phos-
phate-guanine oligodeoxynucleotides (CpG ODN) are 
immunostimulatory DNA molecules that mimic the immu-
nostimulatory activity of bacterial DNA (38,39). CpG DNA 
motifs strongly activate the mammalian innate immune 
system by interacting with various immune cells via endo-
somal Toll-like receptor 9 (TLR9) (40,41). Upon the stimu-
lation by CpG DNA, immune cells could secret a variety of 
proinflanmiatory and antiviral cytokines including tumor 
necrosis factor-alpha (TNF-alpha, or TNF-a), interleukin-6 
(IL-6), interleukin-12 (IL-12) and interferon (IFN), which 
leads to potent immune response. The therapeutic potential 
of CpG DNA has also been extensively explored in both 
basic research and human clinical trials, including the devel-
opment of new vaccine adjuvants, anticancer agents, immu-
noprotective agents and anti-allergic agents (42-45). 
Recently, several groups have reported the utilization of 
DNA nano structures such as DNA tetrahedrons ( 46), DNA 
polypod-like structures ( 47), DNA origami structures ( 48), 
Y-shaped DNA ( 49) and DNA dendrimers (50) to deliver 
immunostimulatory CpG DNA. In this work, to the best of 
our knowledge, we report the first use of RNA nanostruc-
tures to deliver CpG DNA in vitro and in vivo. The immu-
nostimulatory efficacy of RNA polygons was evaluated by 
The presently-described subject matter is further illus-
trated by the following specific but non-limiting examples. 
The following examples may comprise compilations of data 
that are representative of data gathered at various times 
during the course of development and experimentation 
related to the present invention. 
65 measuring the release of cytokines. We found that the 
induction of cytokines is highly dependent on the number of 
CpG per polygon. With increasing number of CpG per 
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polygon, stronger immune response was observed, demon-
strating the advantage of the transition from a triangle to a 
pentagon that can carry five CpGs. 
24 
Materials and Methods 
RNANanoparticles Design, Synthesis and Self-Assembly 
The 3WJ crystal structure of the pRNA molecule (PDB 
ID: 4KZ2) was primarily used for designing polygon models 
5 
using Swiss PDB viewer, as previously described (51). RNA 
strands for corresponding triangle, square and pentagon, 
were synthesized by in vitro T7 transcription using poly-
merase chain reaction (PCR) generated DNA templates. 
We also report RNA CpG. The characteristic of RNA that 
differentiates it from DNA is the 2'-hydroxyl (2'-OH) on 
each ribose sugar of the backbone. The 2'-OH group offers 
RNA a special property. From a structural point of view, the 
advantage of this additional hydroxyl group is that it locks 
the ribose sugar into a 3'-endo chair conformation, and it will 
10 be structurally favorable for the RNA double helix to adopt RNAs were purified by denaturing polyacrylamide gel elec-
trophoresis (PAGE) and were either Cy5 whole body RNA 
labeled (Minis Bio LLC) or 5'-end [-32P] ATP (Perki-
nElmer) labeled, as previously described (8). 
the A-form helix rather than the B-form helix that is typi-
cally present in the DNA. From a thermodynamic point of 
view, remarkably, the RNA double helix is more thermody-
namically stable than the DNA double helix considering 15 
llG0 for RNA double helix formation is -3.6 to -8.5 
RNA polygons were assembled in one pot by mixing 
equimolar concentrations (final concentration of 1 IIM) of 
four RNA strands for the triangle, five RNA strands for the 
square and six RNA strands for the pentagon in 1 xTMS 
buffer (50 mM TRIS pH 8.0, 100 mM NaCl and 10 mM 
kJmol-1 per base pair stacked and llG0 for DNA double 
helix formation is -1.4 kJmol-1 per base pair stacked. 
Moreover, the presence of special structures such as bends, 
stacks, junctions and loops in the 3D structure of RNA as 
well as various proteins and metal ions may also further 
improve its stability. Similar to DNA CpG sequence, RNA 
CpG sequence can also induce immune response and can be 
applied to the development of cancer immunotherapy and 
vaccine adjuvants. 
Triangle 
strand A 
Triangle 
Strand B 
Triangle 
Strand C 
Triangle 
Strand D 
20 MgC12). Samples were annealed for 1 h in a thermocycler 
with controlled, slow cooling (1 ° C./min) from 80 to 4° C. 
All RNA polygons harboring CpG ODNs were assembled 
from their corresponding 2'F-U/C modified strands in one 
pot. 
The three short RNA strands and one long RNA strands 
for assembly of the RNA polygon are provided in Table 1. 
TABLE 1 
RNA Triangle Nanostructure 
SEQ. 
RNA Sequence ID NO 
short 5'GGGAGCCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUG 1 
UUGCACGCAC -3' 
Short 5'GGGAGCGUGCAAUCAUGGCAACGAUAGAGCAUACUUUG 2 
UUGGCUGGAC -3' 
Short 5'GGGACCAGCCAAUCAUGGCAAUAUACACGCAUACUUUG 3 
UUGACGGCGG -3' 
Long 5'GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUG 4 
UAUGCUCUAUCGUUGUCAUGUGUAUGGC -3' 
The four short strands and one long strand for assembly 
of the square RNA nanostructure are provided in Table 2. 
TABLE 2 
RNA Square Nanostructure 
RNA Sequence SEQ. ID NO 
Square Short 5'GGGAGCCGUCAAUCAUGGCAAGUGUCCGCCAUAC 5 
Strand A UUUGUUGCACGCAC -3' 
Square Short 5'GGGAGCGUGCAAUCAUGGCAAGCGCAUCGCAUAC 6 
Strand B UUUGUUGCGACCUA -3' 
Square Short 5'GGGAGGUCGCAAUCAUGGCAACGAUAGAGCAUA 7 
Strand C CUUUGUUGGCUGGAC -3' 
Square Short 5'GGGACCAGCCAAUCAUGGCAAUAUACACGCAUAC 8 
Strand D UUUGUUGACGGCGG -3' 
Square Long 5'GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUC 9 
Strand E AUGUGUAUGCUCUAUCGUUGUCAUGUGUAUGCGA 
UGCGCUUGUCAUGUGUAUGGC -3' 
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The five short strands and one long strand for assembly of 
the pentagon RNA nanostructure are provided in Table 3. 
TABLE 3 
RNA Pentagon Nanostructure 
RNA Sequence 
Pentagon Short 5'GGGAGCCGUCAAUCAUGGCAAGUGUCCGCCAUAC 
Strand A UUUGUUGUAGGGCA -3' 
Pentagon Short 5'GGGACCCUACAAUCAUGGCAAAUAUGCGCCAUAC 
Strand B UUUGUUGCACGCAC -3' 
Pentagon Short 5'GGGAGCGUGCAAUCAUGGCAAGCGCAUCGCAUAC 
Strand C UUUGUUGCGACCUA -3' 
Pentagon Short 5'GGGAGGUCGCAAUCAUGGCAACGAUAGAGCAUA 
Strand D CUUUGUUGGCUGGAG -3' 
Pentagon Short 5'GGGACCAGCCAAUCAUGGCAAUAUACACGCAUAC 
Strand E UUUGUUGACGGCGG -3' 
Pentagon Long 5'GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUC 
Strand F AUGUGUAUGCUCUAUCGUUGUCAUGUGUAUGCGA 
UGCGCUUGUCAUGUGUAUGGCGCAUAUUUGUCAUG 
UGUAUGGC -3' 
Table 4 provides sequences for CpG motifs. 
A21 CpG 
B21 CpG 
C21 CpG 
TABLE 3 
CG motifs 
RNA Sequence 
5'-UCCAUGACG UUCCUGACGU UUUUUUUACA 
GUCGUAUUGC AUUCCGA-3' 
5'-TCCATGACG TTCCTGACGT TTTTTTTACA 
GTCGTATTGC ATTCCGA-3' 
5'-UCCAUGACGU UCCUGACGUU UUUUUCCAUA 
CCGCCAUUUC CAACUA-3' 
5'-TCCATGACGT TCCTGACGTT TTTTTCCATA 
CCGCCATTTC CAACTA-3' 
5'-UCCAUGACGU UCCUGACGUU UUUUUAAGCA 
CAUGCGAUGU UUAACU-3' 
5'-TCCATGACGT TCCTGACGTT TTTTTAAGCA 
CATGCGATGT TTAACT-3' 
SEQ. 
ID NO 
16 
17 
18 
19 
20 
21 
Table 5 provides the sequences for the RNA Triangle 
harboring the RNA CpG motif. 
TABLE 5 
RNA Triangle Nanostructure Harboring RNA CpG motif 
SEQ. ID NO 
25 
10 
11 
12 
13 
14 
15 
Native PAGE, Temperature Gradient Gel Electrophoresis 
(TGGE) and Boiling Resistance Assays 
RNA assemblies were evaluated on 7% (29:1) native 
poly-acrylamide gels in the presence of 0.5xTMS buffer. 
30 Gels were run at constant 90 V, +4 ° C. Gels were imaged 
with Typhoon FLA 7000 (GE Healthcare) to visualize RNA 
strands. Temperature gradient gel electrophoresis (TGGE) 
analysis was performed on 7% native PAGE in a buffer 
containing 50 mM TRIS pH 8.0, 100 mM NaCl and 0.2 mM 
35 MgC12, as previously described (14, 26, 28). A gradient 
temperature of 30-70° C. was applied perpendicular to 
electrical current and the experiment was run for 1 h at 20 
W. A total RNA concentration of 100 nM was used in TGGE 
40 analysis. Apparent TM values corresponded to the tempera-
ture at which half of the polygons fractions were dissociated 
and apparent KD values for multiple RNA strands were 
calculated, as described previously (7). 
Boiling resistance assay was performed in 10 III contain-
45 ing 1 IIM preassembled polygons in TMS buffer or in the 
presence of SM urea. Samples were incubated at 100° C. for 
several minutes, then snap cooled on dry ice to prevent 
refolding following evaluation on 7% native PAGE at 4° C. 
Individual experiments were repeated several times to 
50 reduce error. 
Quantification analysis was performed using ImageJ (52). 
RNA Sequence and 
DNA Sequence 
SEQ. 55 
Equal-sized boxes were drawn around the lanes correspond-
ing to the triangle, square, or pentagon complexes and 
corresponding quantified values for each type of polygon 
were divided by the sum of the values presented in the 
corresponding lane. 
Tri A-CpG 5'- GGUCCAUGAC GUUCCUGACG UUUUUUUGGG 
CCGUCAAU CAUGGCAAGU GUCCGC CAUAC UUU 
GUUGCACGCC C -3' 
ID NO 
22 
Tri B-CpG 5'- GGUCCAUGAC GUUCCUGACG UUUUUUUGGG 23 
CGUGCAAU CAUGGCAACG AUAGAGCAUA C UUU 
GUUGGCUGGC C -3' 
Tri C-CpG 5'- GGUCCAUGAC GUUCCUGACG UUUUUUUGGC 24 
CAGCCAAU CAUGGCAAUA UACACGCAUA C UUU 
GUUGACGGCC C -3' 
Cell Cultures 
Mouse macrophage-like RAW 264.7 cells were grown in 
Dulbecco's Modified Eagle's Medium supplemented with 
60 10% fetal bovine serum, 100 units/ml penicillin and 100 
mg/ml streptomycin at 37° C. in humidified air containing 
5% CO2. Cells were then seeded on 24-well plates or 
96-well plates at a density of 5x105 cells/ml and cultured 
overnight before use. 
65 Cytokine Secretion from RAW264.7 Cells 
RAW 264.7 cells were plated into 24-well plates with the 
density of 2.5x105 cells per well and cultured overnight. 
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Then, RNA nanoparticles harboring different numbers of 
CpG ODNs were diluted in Opti-MEM medium (Life Tech-
nologies Corporation, Carlsbad, Calif., USA) and added to 
the cells. The cells were continually cultured for 8 hat 37° 
C. in humidified air containing 5% CO2, and the cell culture 5 
supernatant were collected and stored at -80° C. until use. 
The concentration of TNF-a and IL-6 in the supernatant 
were determined by enzyme-linked immunosorbent assay 
(ELISA) using Mouse ELISA MAX™ Deluxe sets (BioLe-
gend, Inc., San Diego, Calif.), following protocols provided 10 
by the manufacturer. 
Cytokine Secretion from Mice 
Male CD-1 mice ( 4-5 weeks old) were purchased from 
Charles River Laboratories. All animal procedures were 15 
approved by the Institutional Animal Care and Use Com-
mittee at University of Kentucky and were performed in 
accordance with guidelines issued by the National Institutes 
of Health for the care of laboratory animals. For in vivo 
immunostimulation, RNA triangular nanoparticles harbor- 20 
ing CpG ODN, RNA triangular nanoparticles, or CpG ODN 
were dissolved in phosphate buffered saline (PBS) and 
administrated to the mice via tail vein injection at 2 mg/kg 
(CpG ODN per body weight). The same volume of PBS was 
injected into a mouse as a control. Blood samples were 25 
collected 3 h post-injection by cardiac puncture. Serum was 
prepared by centrifugation at 12 800 g for 10 min. Serum 
TNF-a and IL-6 levels were determined by enzyme-linked 
immunosorbent assay (ELISA) using Mouse ELISA 
MAX™ Deluxe sets (BioLegend, Inc., San Diego, Calif., 30 
USA), following protocols provided by the manufacturer. 
Confocal Microscopy Imaging 
RAW 264.7 cells were seeded on glass coverslips in 
24-well plates and cultured at 37° C. in humidified air 35 
containing 5% CO2 overnight. The culture medium was 
removed and the cells were washed with Opti-MEM 
medium twice to remove dead cells. RNA nanoparticles 
harboring Cy3-labeled CpG DNA or Cy3-labeled CpG DNA 
only were diluted in Opti-MEM medium and added to the 40 
cells. After 4 h incubation at 37° C. in humidified air 
28 
Flow Cytometry Assay 
RAW264.7 cells were detached from the cell culture flask 
by using a cell scraper. The cells were washed with Opti-
MEM medium and aliquot in 1.5 mL Eppendorf tubes at the 
density of 5xl 05 cells per tube. RNA nanoparticles harbor-
ing Cy3-labeled CpG DNA or Cy3-labeled CpG DNA only 
were diluted in Opti-MEM medium and incubated with the 
cells at 37° C. for 1.5 h. The cells were vortexed every 30 
min during the incubation. After washing with PBS, the cells 
were resuspended in PBS and the intensity of fluorescence 
was determined by FACSCalibur flow cytometer (BD Bio-
sciences, San Jose, Calif.). 
Cytotoxicity Assay 
The cytotoxicity of RNA nanoparticles harboring CpG 
ODNs was evaluated with an MTT assay kit (Promega, 
Madison, Wis.), according to the protocol provided by the 
manufacturer. Briefly, RAW 264.7 cells were seeded at 96 
well plates and cultured overnight at 3 7° C. in humidified air 
containing 5% CO2. RNA nanoparticles harboring CpG 
ODNs and controls were dissolved in fresh cell culture 
medium at the indicated concentrations and added to the 
cells for incubation at 3 7° C. for 24 h. Then, 15 µL of the dye 
solution was added to each well, followed by a 4 h incuba-
tion at 37° C., Next, 100 µl of the solubilization solution was 
added to each well and the plate was future incubated at 
room temperature on a plate shaker until the formazan 
crystals were completely solubilized. The absorbance was 
measured at 570 nm using a microplate reader. The cell 
viability was calculated relative to the absorbance of the cell 
only control (viability of cell only control=!). 
RNA Polygons: Triangle, Square and Pentagon Fabrica-
tion and Self-Assembly 
The structural features of the recently discovered ultrast-
able pRNA 3WJ module from the bacteriophage Phi29 DNA 
packaging motor were utilized for in silica design of the 
RNA triangle, square and pentagon 2D polygons. During the 
computer modeling we used the particular angle of the 3WJ 
formed by Hl and H2 as an inner angle of the polygons as 
we hypothesized that the angle could be stretched to a more 
open conformation. Throughout this report the intra-helical 
angle between Hl and H2 is denoted as LAOB, as shown in 
FIG. 1. Each RNA model contained a pRNA 3WJ motif at 
each vertex, and the inner angles correspond to LAOB. The 
resulting 3D models exhibited flat conformations, as 
containing 5% CO2, the cells were washed twice with PBS 
and fixed with 4% formaldehyde. ProLong R GoldAntifade 
Reagent with DAPI (Life Technologies Corporation, Carls-
bad, Calif.) was used to stain the cell nucleus and mount the 
samples. Alexa FluorR 488 phalloidin (Life Technologies 
Corporation, Carlsbad, Calif., USA) was used to stain actin. 
The images were obtained on a Olympus FVl 000 confocal 
microscope (Olympus Corporation, Tokyo, Japan). 
45 expected from the plane geometry of the 3WJ motif (51) 
(FIG. 2A). As used herein, vertex refers to a point of an 
angle, such as LAOB, and vertex refers to a corner of a 
polygon. By way of example, and with reference FIG. 2B, 
the triangular polygon defined by internal strand D and 
Atomic Force Microscopy Imaging 50 external strands A, B, and C, includes three vertexes; the 
square polygon defined by internal strand E and external 
strands A, B, C, and D, includes four vertexes; and the 
pentagon polygon defined by internal strand F and external 
RNA polygons were imaged with MultiModeAFM Nano-
Scope IV system (Veeco ), as per previously reported meth-
ods (61). Briefly, the RNA samples were diluted with 
lxTMS buffer to a final concentration of 3-5 nM. Then, 
droplets of samples ( 5-10 L) were immediately deposited on 55 
APS mica. After 2 min incubation on the specifically modi-
fiedAPS mica surface (41;42), excess samples were washed 
with DEPC treated water and dried under a flow of Argon 
gas. AFM images in air were acquired using MultiMode 
AFM NanoScope IV system (Veeco/Digital Instruments, 
Santa Barbara, Calif.) operating in tapping mode. 
strands A, B, C, D, and E, includes five vertexes. 
Each polygon was composed of a different number of 
RNA strands classified as short strands (external) and long 
strands (internal) (FIG. 2B). By increasing the number of 
external strands and the propagation of the central or internal 
strand, the tension on the inter-helical LAOB increased to 
60 60°, 90° and 108°, allowing for 2D formation of correspond-
ing triangle, square and pentagon shapes. The measured 
widths, from one corner to another, were 10.2 nm, while the 
heights differed as follows: triangle=9.1 nm, square=l0.2 
nm and pentagon=12.7 nm. Following the transcription of 
Dynamic Light Scattering 
Apparent hydrodynamic sizes of preassembled triangle, 
square, and pentagon complexes (10 µM) in 504, TMS 
buffer were measured by Zetasizer nano-ZS (Malvern 
Instrument, LTD) at 25° C. The laser wavelength was 633 
nm. 
65 individual RNA strands, self-assembly properties of the 
triangle, square and pentagon designs were evaluated on 7% 
native polyacrylamide gel electrophoresis (PAGE) (FIG. 
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larger than the real diameter due to tip size used (54) and the 
resolution of imaging equipment. Nevertheless, the two 
techniques demonstrated that the relative size of the nano-
particles increased from triangle to square to pentagon. 
Accordingly, native PAGE, AFM and DLS showed the 
formation of compact molecular 2D assemblies of triangle, 
square and pentagon based on the pRNA 3WJ LAOB. 
Consequently, the naturally preserved 60° LAOB could 
be stretched to reach the formation of square and pentagon. 
2C). All polygon formations were obtained by one-step 
self-assembly (7, 10, 11, 19). Each RNA component of 
corresponding nanoparticles were whole chain labeled with 
Cy5 to evaluate participation of all RNA strands in their 
corresponding assemblies. Yield of correctly assembled 5 
polygons was estimated to be >90% based on native PAGE 
gel evaluations. Equilibrium constants of dissociation were 
obtained from apparent KD gels, and KD values were 
determined to be 18.8, 20.3 and 22.5 nM for triangles, 
squares and pentagons, respectively (FIGS. 7 and 8). 
These results demonstrate that each RNA nanoparticle 
assembles into the desired nanostructure, and indicated by a 
stretching of the 60. LAOB to wider conformations. The 
assembly of RNA strands into specific-shaped nanoparticles 
based on the 60. LAOB of the pRNA 3WJ motif was 15 
controlled by modulating the number of short external 
stands and the length of the long internal strand. 
10 The stretching, or tension, that the angle underwent could 
have had a significant impact on the overall stability of the 
nanoparticles. Therefore, it was of great interest to evaluate 
and compare the polygon's stabilities. 
Structural Characterization of Polygons by Atomic Force 
Microscopy (AFM) and DLS 
Stability Comparison Between Triangle, Square and Pen-
tagon 
TGGE Investigation of Polygon Stability 
The stabilities of polygons were studied using a perpen-
dicular TGGE (Biometra GmbH). This convenient tech-
nique has garnered widespread use for measuring melting 
temperatures of RNA nanoparticles with multiple strands (5, 
7, 14, 26, 28, 55). The preassembled polygons were sub-
jected to 7% native TGGE with a gradient temperature of 
30-70° C. perpendicular to electrical current. The following 
apparent TM values were obtained for the polygons at 100 
nM total concentration (Ct) in presence of 0.2 mM MgC12: 
triangle TM=56° C., square TM=53° C. and pentagon 
TM=50° C. (FIG. 4A). The triangular nanoscaffolds were 
more stable than squares and pentagons, although the num-
ber of RNA bp was much higher in the pentagon construct, 
as compared to the square and triangle. Usually, the stability 
of nucleic acids with the same base-pair content is directly 
dependent on metal ion and total nucleic acid concentra-
tions. Since these two criteria were the same, it was assumed 
that the higher the number of bp in a given RNA structure 
To further evaluate the size and shape of the resulting 20 
RNA assemblies, structural characterization of each polygon 
was conducted by AFM. AFM images of the pRNA 3WJ 
based polygons revealed that the shapes of resulting poly-
gons were similar to their predicted, theoretical 3D models 
(FIG. 3A). The estimated average dimensions were found to 25 
be 13±1.1, 14±1.8 and 17±1.6 nm for triangles, squares and 
pentagons, respectively. These values do not reflect the true 
sizes of the RNA polygons due to the AFM tip convolution, 
but rather demonstrate that the average size of the nanopar-
ticles increases from triangle to pentagon. In addition, the 30 
central cavity of each RNA shape is visible, and the size of 
the cavity gradually increases with the number of polygon 
vertices. The measured heights for all nanoparticles was 
found to be 2 nm, in agreement with previously reported 
heights of nucleic acid double helices (26,53). 35 the higher the stability. Therefore, the most stable shape 
produced should be the pentagon. However, based on TGGE 
data the opposite was found. This was likely due to the 
tension caused by the stretching of the native pRNA 3WJ 
Quantification analysis was performed to compare appar-
ent yields between polygons observed on AFM mica sur-
face. 
Equal concentrations (1 nM) of the polygons were depos-
ited on a mica surface and correctly folded polygons were 40 
manually counted in a 0.5 µm2 area, resulting in 48 trian-
gular particles, 33 square particles and 17 pentagon nano-
particles (FIG. 9). The estimated number of triangular nano-
particles adsorbed on the mica was 1.5 times more than that 
of the square and three times more than that of the pentagon. 45 
However, native PAGE revealed that the yields among the 
three polygons were almost equal. The difference in adsorp-
tion amounts between polygons on the mica surface was 
presumably due to variation in their sizes and 3D confor-
mations, resulting in different dynamic and physical prop- 50 
erties. 
Hydrodynamic Diameters of the Polygons by DLS was 
performed to determine the apparent hydrodynamic diam-
eters for each of the polygons. 
60° LAOB. The triangular construct angle was preserved 
(60°), the square and pentagon angles were stretched to the 
wider conformations of 90° and 108°, respectively. Previ-
ously it has been shown that any nucleotide mutations or 
deletions within the native core structure of the pRNA 3WJ 
motif would also result in the loss of its thermodynamic 
stability (10). Interestingly, the measured triangle and square 
TM values differed by +3° C., as did the square and 
pentagon. Boiling resistance assay in the presence and 
absence of 8 M urea further confirmed that the triangle was 
the most stable nanoparticle (FIG. 4B). The quantification of 
nanoparticle bands after heating to 100° C. resulted in 
75±4% recovery of the triangular assembly, suggesting a 
TM> 100° C. By definition, TM is the measured temperature 
when half the RNA concentration has melted, i.e. 50% 
recovery. The percentage of recovery for square was 28±2% 
55 and for pentagon was 16±5%, much lower than the value 
estimated for triangle recovery. The experiment with the 
presence of 8 M urea in boiling solution showed that the 
overall trend of stability remained the same, but the per-
centage of recovery was 55±4% for triangle, 8±3% for 
DLS was performed to determine the apparent hydrody-
namic diameters for each of the polygons. The diameters 
were found to be 9 .1, 11.2 and 13 .5 nm for triangles, squares 
and pentagons, respectively (FIG. 3B). The increase in 
number of 3WJ cores corresponds with the larger observed 
diameter. The measured diameters agreed with their corre-
sponding 3D models. However, there was a discrepancy 
between polygon sizes determined by AFM and DLS. This 
could be attributed to the fundamentally different tech-
niques, as DLS determines the average size distribution 
profile of nanoparticles in solution assuming that the poly- 65 
gons have globular shapes [refer to manual at http://www. 
malvern.com], while AFM imaging can produce images 
60 square and no pentagon fraction was detected. Overall, the 
nanoparticle with fewer 3WJ motifs (triangle) resulted in a 
higher thermostability and resistance in chemical degrada-
tion and the change in stability was in large part due to the 
stretching of the LAOB. 
Toxicity Assay for CpG-RNA Polygons 
The modulation effect of triangle, square and pentagon 
harboring immunologic adjuvant CpG oligonucleotide is an 
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immunological adjuvant popularly used as vaccine adjuvant 
or immunotherapy reagent for disease control and treatment 
32 
This observation was further confirmed by confocal 
microscopy images (FIG. 6B) revealing that RNA nanopar-
ticle harboring CpGs are localized in the cytoplasm exclu-
sively and that there are much higher amounts of triangular 
nanoparticles inside the cell compared to free CpG, suggest-
ing that RNA nanoparticles could efficiently enhance the 
cellular uptake of the CpG adjuvants. 
Collectively, both flow cytometry and confocal imaging 
demonstrated that all RNA nanoparticles with different 
( 42). To evaluate whether RNA polygons can enhance the 
immunomodulation effect, CpG oligonucleotide was incor-
porated with each RNA polygon using one-pot self-assem- 5 
bly (FIGS. 10-12). The toxicity assay for the resulting 
complexes revealed no toxicity; moreover the RNA poly-
gon-CpG complexes induced cell proliferation during the 
incubation period, as compared to the cell only control (FIG. 
13). 10 shape and harboring CpGs have much stronger binding and 
cellular entry to the macrophage-like RAW 264.7 cells 
compared to free CpGs. In addition, cellular uptake was 
highly dependent on the number of CpG per polygon. With 
Measurement of the Release of TNF-Alpha and IL-6 
Cytokines 
The extracellular immunostimulatory efficacy of RNA 
polygons was evaluated by measuring the release of cytok-
ines TNF-a and IL-6 after addition to mouse macrophage- 15 
like RAW264.7 cells (FIGS. SA and B), as previously 
described ( 56,57). The triangular RNA nanoparticle coupled 
with only one CpG exhibited the highest level of cytokine 
induction for both TNF -a and IL-6 compared to square and 
pentagonal RNA nanoparticles. Increasing the number of 20 
CpG per nanoparticle yielded the opposite effect, as pen-
tagonal RNA nanocarriers showed the highest level of the 
induction of both TNF-a and IL-6 presumably due to the 
increased local CpG concentration. The results suggest that 
the cytokine release by CpG coupled to RNA polygons with 25 
different shapes remarkably increases the immunostimula-
tory activity compared to CpG alone (FIG. 5). RNA particles 
with the size of about 10 nm, such as the triangle, induced 
the greatest amount of TNF-a and IL-6. In addition, the 
induction of cytokines was highly dependent on the number 30 
of CpG per polygon. With increasing number of CpG per 
polygon, a stronger immune response is observed (FIG. SC), 
demonstrating an advantage of transiting from triangle to 
pentagon that can carry five CpG oligonucleotides. 
the increasing number of CpG per polygon, more efficient 
cell entry was observed (FIG. SC), demonstrating the advan-
tage of the transition from triangle to pentagon nanoparticles 
that can carry five CpG. 
Artificial construction of RNA nanoparticles requires 
knowledge of the structural properties of RNA motifs, such 
as interhelical or intrahelical distances, X-Y and X-Y-Z 
angles, number and orientations of RNA branches in multi-
way junctions, canonical and non-canonical interactions, 
binding sites for proteins, metal ions and small molecules (2, 
10, 16, 25, 51, 60). Progression in RNA structural biology 
allowed for the analysis of RNA 3D motifs from existing 
RNA structures at atomic resolution and various data bases, 
including www.pdb.com, RNA multi-way junction (61) and 
find RNA motif (62). This study, based on the previously 
reported versatile pRNA 3WJ 3D motifs (PDB accession ID: 
4KZ2) (10,51), shows that the 3WJ structure can be folded 
into desired conformations based on the dynamics of the 60° 
Enhancement of Modulation Effect in Animal by Immu- 35 
nological Adjuvant Incorporated into RNA Triangle 
LAOC, demonstrating the ability to tune the physical and 
structural properties of RNA polygons for a variety of 
technological, biological and medicinal needs. This 
approach, based on the propagation of the central RNA 
strand used to direct the folding of corresponding short or 
To examine whether RNA nanoparticles retain their 
immunostimulatory activity in vivo, nanoparticles were 
administered to CD-1 mice by injection into the tail vein at 
2 mg/kg (CpG oligonucleotide per body weight), following 40 
level determination of cytokine TNF-a and IL-6 levels after 
external strands into planar triangle, square and pentagon 
conformations, resulted in the 60°, 90° and 108° bending of 
interhelical LAOC of the pRNA 3WJ. This is especially 
important for medical applications where one needs to 
construct different RNA nano-scaffolds based on a nontoxic 
3 h post-administration in collected blood seflllll. FIG. SD 
shows that free triangle nanoparticles and free CpGs did not 
induce any cytokine production, whereas the complex tri-
angle-CpG resulted in elevated levels of both cytokines. The 45 
difference in immunostimulatory activity of triangle-CpG 
was estimated to be 10-fold compared to free CpG in vivo. 
These data are in agreement with the in vitro stimulation of 
murine RAW264.7 cells. 
and thermodynamically stable building block. The following 
advantages result from this technique: (i) the number and 
combination of therapeutic molecules can be tuned to an 
RNA-based nano-carrier; (ii) the nano-scaffold has a con-
trollable size and shape and (iii) variable thermodynamic 
and RNase resistance properties can be applied depending 
on the application of the nano-scaffold. 
In addition to the discovery of the unique approach for the 
Comparison of Cellular Uptake by Different CpG-RNA 
Polygons 
Previously, it has been demonstrated that the CpG oligo-
nucleotide can be readily recognized by TLR9 on the 
endosomal membrane of macrophages, resulting in cellular 
uptake of the CpG adjuvants (58,59). To investigate whether 
there is a difference between the efficiency of RNA polygons 
binding to the cells, we quantified the cellular uptake of 
polygons-CpG using flow cytometry assay (9,10). FIG. 6A 
demonstrates the binding of different RNA polygon-CpG to 
the RA W264.7 cells in a dose-dependent manner. There was 
an increase in binding efficiency from triangle to pentagon 
with more CpGs (FIG. 14). Notably, all RNA polygons-CpG 
complexes remain intact after 16 h incubation in fetal bovine 
seflllll (FBS) indicating robustness of the assembled com-
plex in extracellular environment (FIG. 15). Overall, RNA 
polygon-CpG complexes exhibit significantly more binding 
efficiency to cells compared to CpG oligonucleotides alone. 
50 rational design of stable RNA nanoparticles, it has been 
demonstrated that each RNA polygon has the potential to 
serve as multivalent nanocarriers of vaccine adjuvants, par-
ticularly of CpG oligodeoxynucleotides. The designed 
RNAs self-assemble into distinct, non-toxic homogeneous 
55 nanoparticles with high chemical, thermal and intracellular 
stability. We found that the size and shape of the RNA 
nanostructures are important factors for the induction of 
immunostimulatory processes in vitro and in animal models 
and that there is a correlation between the cytokine induction 
60 and the local CpG concentration effect. The highest level of 
secretion of pro-inflanimatory cytokines tumor necrosis fac-
tor TNF-a, interleukin (IL)-6 was obtained with the smallest 
nanoparticle (triangle-9 nm size) harboring one CpG com-
pared to square (-11 nm) and pentagon (-13 nm). However, 
65 upon increasing the numbers of CpG per RNA nanoparticle 
the cytokine induction was affected more by pentagon as the 
number or local concentration of CpG is highest in the 
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pentagon. This study illustrates the importance of the size 
and shape of RNA nanoparticles for improvement of activity 
of CpG based vaccines targeting infectious diseases and 
cancer cells, as well as for increasing immune-response by 
the innate and adaptive immune systems. The RNA nano- 5 
particles harboring CpGs are safe, effective, versatile and 
easy to manufacture, offering new solutions to address the 
unmet needs in current vaccines and adjuvants. Recent 
findings on the thermodynamically ultra-stable (10,11) and 
heat-resistant (18) RNA nanoparticles have expanded the 10 
potential for application of pRNA 3WJ derived nanopar-
ticles in the fields of biomedical, nanotechnology, or poly-
mer industries. 
In FIG. 64, cytokine testing of2'F triangle harboring CpG, 15 
DNA triangle harboring DNA CpG and 2'F triangle harbor-
ing 2'F RNA CpG shows increased TNF-a in cell culture 
supernatant in the 2'F Triangle harboring 2'F RNA CpG 
compared to 2'F triangle harboring DNA CpG and DNA 
triangle harboring DNA CpG. 20 
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<160> NUMBER OF SEQ ID NOS, 93 
<210> SEQ ID NO 1 
<211> LENGTH, 48 
<212> TYPE, RNA 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
15 73. U.S. Patent Application Publication No. 2009/0081157 
to Kornbluth et al. for "Immunostiulatory Combinations 
for Vaccine Adjuvants." 
74. International Patent Application Publication No. WO 
2005/003293 to Guo et al. for "pRNA Chimera." 
20 75. International Patent Application Publication No. WO 
2012/170372 to Guo for "pRNA Multivalent Junction 
Domain for Use in Stable Multivalent RNA Nanopar-
ticles." 
All publications, patents, and patent applications men-
25 tioned in this specification, including the Appendixes, are 
herein incorporated by reference to the same extent as if 
each individual publication, patent, or patent application was 
specifically and individually indicated to be incorporated by 
reference. 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 1 
gggagccguc aaucauggca aguguccgcc auacuuuguu gcacgcac 
<210> SEQ ID NO 2 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 2 
gggagcgugc aaucauggca acgauagagc auacuuuguu ggcuggac 
<210> SEQ ID NO 3 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 3 
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcgg 
48 
48 
48 
<210> SEQ ID NO 4 
<211> LENGTH, 66 
<212> TYPE, RNA 
39 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 4 
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug 60 
uauggc 66 
<210> SEQ ID NO 5 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 5 
gggagccguc aaucauggca aguguccgcc auacuuuguu gcacgcac 
<210> SEQ ID NO 6 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 6 
gggagcgugc aaucauggca agcgcaucgc auacuuuguu gcgaccua 
<210> SEQ ID NO 7 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 7 
gggaggucgc aaucauggca acgauagagc auacuuuguu ggcuggac 
<210> SEQ ID NO 8 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 8 
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcgg 
<210> SEQ ID NO 9 
<211> LENGTH, 88 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 9 
48 
48 
48 
48 
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug 60 
40 
41 
uaugcgaugc gcuugucaug uguauggc 
<210> SEQ ID NO 10 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 10 
gggagccguc aaucauggca aguguccgcc auacuuuguu guagggca 
<210> SEQ ID NO 11 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 11 
gggacccuac aaucauggca aauaugcgcc auacuuuguu gcacgcac 
<210> SEQ ID NO 12 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 12 
gggagcgugc aaucauggca agcgcaucgc auacuuuguu gcgaccua 
<210> SEQ ID NO 13 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 13 
gggaggucgc aaucauggca acgauagagc auacuuuguu ggcuggag 
<210> SEQ ID NO 14 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 14 
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcgg 
<210> SEQ ID NO 15 
<211> LENGTH, 110 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polynucleotide 
<400> SEQUENCE, 15 
88 
48 
48 
48 
48 
48 
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug 60 
42 
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-continued 
uaugcgaugc gcuugucaug uguauggcgc auauuuguca uguguauggc 110 
<210> SEQ ID NO 16 
<211> LENGTH, 46 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 16 
uccaugacgu uccugacguu uuuuuuacag ucguauugca uuccga 
<210> SEQ ID NO 17 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 17 
tccatgacgt tcctgacgtt ttttttacag tcgtattgca ttccga 
<210> SEQ ID NO 18 
<211> LENGTH, 46 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 18 
uccaugacgu uccugacguu uuuuuccaua ccgccauuuc caacua 
<210> SEQ ID NO 19 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 19 
tccatgacgt tcctgacgtt tttttccata ccgccatttc caacta 
<210> SEQ ID NO 20 
<211> LENGTH, 46 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 20 
uccaugacgu uccugacguu uuuuuaagca caugcgaugu uuaacu 
<210> SEQ ID NO 21 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 21 
46 
46 
46 
46 
46 
44 
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tccatgacgt tcctgacgtt tttttaagca catgcgatgt ttaact 
<210> SEQ ID NO 22 
<211> LENGTH, 73 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 22 
46 
gguccaugac guuccugacg uuuuuuuggg ccgucaauca uggcaagugu ccgccauacu 60 
uuguugcacg ccc 73 
<210> SEQ ID NO 23 
<211> LENGTH, 73 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 23 
gguccaugac guuccugacg uuuuuuuggg cgugcaauca uggcaacgau agagcauacu 60 
uuguuggcug gee 73 
<210> SEQ ID NO 24 
<211> LENGTH, 73 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 24 
gguccaugac guuccugacg uuuuuuuggc cagccaauca uggcaauaua cacgcauacu 60 
uuguugacgg ccc 73 
<210> SEQ ID NO 25 
<211> LENGTH, 63 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 25 
taatacgact cactatatcc atgacgttcc tgacgttttt tttacagtcg tattgcattc 60 
cga 63 
<210> SEQ ID NO 26 
<211> LENGTH, 38 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 26 
taatacgact cactatatcc atgacgttcc tgacgttt 
<210> SEQ ID NO 27 
<211> LENGTH, 37 
<212> TYPE, DNA 
38 
46 
47 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 27 
tcggaatgca atacgactgt aaaaaaaacg tcaggaa 
<210> SEQ ID NO 28 
<211> LENGTH, 63 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 28 
37 
taatacgact cactatatcc atgacgttcc tgacgttttt ttccataccg ccatttccaa 60 
eta 63 
<210> SEQ ID NO 29 
<211> LENGTH, 38 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 29 
taatacgact cactatatcc atgacgttcc tgacgttt 
<210> SEQ ID NO 30 
<211> LENGTH, 37 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 30 
tagttggaaa tggcggtatg gaaaaaaacg tcaggaa 
<210> SEQ ID NO 31 
<211> LENGTH, 63 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 31 
38 
37 
taatacgact cactatatcc atgacgttcc tgacgttttt ttaagcacat gcgatgttta 60 
act 63 
<210> SEQ ID NO 32 
<211> LENGTH, 38 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 32 
taatacgact cactatatcc atgacgttcc tgacgttt 38 
48 
<210> SEQ ID NO 33 
<211> LENGTH, 37 
<212> TYPE, DNA 
49 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 33 
agttaaacat cgcatgtgct taaaaaaacg tcaggaa 
<210> SEQ ID NO 34 
<211> LENGTH, 14 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 34 
uugucaugug uaug 
<210> SEQ ID NO 35 
<211> LENGTH, 13 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 35 
cauacuuugu uga 
<210> SEQ ID NO 36 
<211> LENGTH, 13 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 36 
ucaaucaugg caa 
<210> SEQ ID NO 37 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 37 
gggagccguc aaucauggca aguguccgcc auacuuuguu gcacgcac 
<210> SEQ ID NO 38 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 38 
gggagcgugc aaucauggca acgauagagc auacuuuguu ggcuggac 
<210> SEQ ID NO 39 
50 
37 
14 
13 
13 
48 
48 
<211> LENGTH, 48 
<212> TYPE, RNA 
51 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 39 
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcgg 
<210> SEQ ID NO 40 
<211> LENGTH, 66 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 40 
48 
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug 60 
uauggc 66 
<210> SEQ ID NO 41 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 41 
gggagccguc aaucauggca aguguccgcc auacuuuguu gcacgcac 
<210> SEQ ID NO 42 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 42 
gggagcgugc aaucauggca agcgcaucgc auacuuuguu gcgaccua 
<210> SEQ ID NO 43 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 43 
gggaggucgc aaucauggca acgauagagc auacuuuguu ggcuggac 
<210> SEQ ID NO 44 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 44 
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcgg 
48 
48 
48 
48 
52 
<210> SEQ ID NO 45 
<211> LENGTH, 88 
<212> TYPE, RNA 
53 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 45 
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug 60 
uaugcgaugc gcuugucaug uguauggc 88 
<210> SEQ ID NO 46 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 46 
gggagccguc aaucauggca aguguccgcc auacuuuguu guagggca 
<210> SEQ ID NO 47 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 47 
gggacccuac aaucauggca aauaugcgcc auacuuuguu gcacgcac 
<210> SEQ ID NO 48 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 48 
gggagcgugc aaucauggca agcgcaucgc auacuuuguu gcgaccua 
<210> SEQ ID NO 49 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 49 
gggaggucgc aaucauggca acgauagagc auacuuuguu ggcuggag 
<210> SEQ ID NO 50 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 50 
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcgg 
48 
48 
48 
48 
48 
54 
<210> SEQ ID NO 51 
<211> LENGTH, 110 
<212> TYPE, RNA 
55 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polynucleotide 
<400> SEQUENCE, 51 
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug 60 
uaugcgaugc gcuugucaug uguauggcgc auauuuguca uguguauggc 110 
<210> SEQ ID NO 52 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 52 
tccatgacgt tcctgacgtt tttttaagca catgcgatgt ttaact 
<210> SEQ ID NO 53 
<211> LENGTH, 71 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 53 
46 
gggagccguc aaucauggca aguguccgcc auacuuuguu gcacgcucuc ucggaaugca 60 
auacgacugu a 71 
<210> SEQ ID NO 54 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 54 
tccatgacgt tcctgacgtt ttttttacag tcgtattgca ttccga 
<210> SEQ ID NO 55 
<211> LENGTH, 71 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 55 
46 
gggagcgugc aaucauggca acgauagagc auacuuuguu ggcuggucuc uaguuggaaa 60 
uggcgguaug g 71 
<210> SEQ ID NO 56 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
56 
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-continued 
<400> SEQUENCE, 56 
tccatgacgt tcctgacgtt tttttccata ccgccatttc caacta 
<210> SEQ ID NO 57 
<211> LENGTH, 71 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 57 
46 
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcucuc aguuaaacau 60 
cgcaugugcu u 71 
<210> SEQ ID NO 58 
<211> LENGTH, 66 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 58 
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug 60 
uauggc 66 
<210> SEQ ID NO 59 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 59 
tccatgacgt tcctgacgtt tttttaagca catgcgatgt ttaact 
<210> SEQ ID NO 60 
<211> LENGTH, 71 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 60 
46 
gggagccguc aaucauggca aguguccgcc auacuuuguu gcacgcucuc ucggaaugca 60 
auacgacugu a 71 
<210> SEQ ID NO 61 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 61 
tccatgacgt tcctgacgtt ttttttacag tcgtattgca ttccga 
<210> SEQ ID NO 62 
<211> LENGTH, 71 
46 
58 
59 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 62 
gggagcgugc aaucauggca agcgcaucgc auacuuuguu gcgaccucuc auugaucuau 60 
gaucguacga u 71 
<210> SEQ ID NO 63 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 63 
tccatgacgt tcctgacgtt tttttatcgt acgatcatag atcaat 
<210> SEQ ID NO 64 
<211> LENGTH, 71 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 64 
46 
gggaggucgc aaucauggca acgauagagc auacuuuguu ggcuggucuc uaguuggaaa 60 
uggcgguaug g 71 
<210> SEQ ID NO 65 
<211> LENGTH, 117 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polynucleotide 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Combined DNA/RNA Molecule, 
Synthetic polynucleotide 
<400> SEQUENCE, 65 
tccatgacgt tcctgacgtt tttttccata ccgccatttc caactaggga ccagccaauc 60 
auggcaauau acacgcauac uuuguugacg gcucucaguu aaacaucgca ugugcuu 117 
<210> SEQ ID NO 66 
<211> LENGTH, 88 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 66 
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug 60 
uaugcgaugc gcuugucaug uguauggc 88 
<210> SEQ ID NO 67 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
60 
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-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 67 
tccatgacgt tcctgacgtt tttttaagca catgcgatgt ttaact 
<210> SEQ ID NO 68 
<211> LENGTH, 71 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 68 
46 
gggagccguc aaucauggca aguguccgcc auacuuuguu guagggucuc auguuaagua 60 
acgucuagaa u 71 
<210> SEQ ID NO 69 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 69 
tccatgacgt tcctgacgtt tttttattct agacgttact taacat 
<210> SEQ ID NO 70 
<211> LENGTH, 71 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 70 
46 
gggacccuac aaucauggca aauaugcgcc auacuuuguu gcacgcucuc gaaagcuugu 60 
agcuauaguu a 71 
<210> SEQ ID NO 71 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 71 
tccatgacgt tcctgacgtt ttttttaact atagctacaa gctttc 
<210> SEQ ID NO 72 
<211> LENGTH, 71 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 72 
46 
gggagcgugc aaucauggca agcgcaucgc auacuuuguu gcgaccucuc auugaucuau 60 
gaucguacga u 71 
62 
<210> SEQ ID NO 73 
<211> LENGTH, 46 
<212> TYPE, DNA 
63 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 73 
tccatgacgt tcctgacgtt tttttatcgt acgatcatag atcaat 
<210> SEQ ID NO 74 
<211> LENGTH, 71 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 74 
46 
gggaggucgc aaucauggca acgauagagc auacuuuguu ggcuggucuc uaguuggaaa 60 
uggcgguaug g 71 
<210> SEQ ID NO 75 
<211> LENGTH, 46 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 75 
tccatgacgt tcctgacgtt tttttccata ccgccatttc caacta 
<210> SEQ ID NO 76 
<211> LENGTH, 71 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 76 
46 
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcucuc aguuaaacau 60 
cgcaugugcu u 71 
<210> SEQ ID NO 77 
<211> LENGTH, 110 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polynucleotide 
<400> SEQUENCE, 77 
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug 60 
uaugcgaugc gcuugucaug uguauggcgc auauuuguca uguguauggc 110 
<210> SEQ ID NO 78 
<211> LENGTH, 64 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
64 
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-continued 
<400> SEQUENCE, 78 
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug 60 
uaug 64 
<210> SEQ ID NO 79 
<211> LENGTH, 27 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 79 
gggccgucaa ucauggcaag uguccgc 
<210> SEQ ID NO 80 
<211> LENGTH, 46 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 80 
ggccagccaa ucauggcaau auacacgcau acuuuguuga cggccc 
<210> SEQ ID NO 81 
<211> LENGTH, 46 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 81 
gggcgugcaa ucauggcaac gauagagcau acuuuguugg cuggcc 
<210> SEQ ID NO 82 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 82 
cauacuuugu ugcacgccc 
<210> SEQ ID NO 83 
<211> LENGTH, 67 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 83 
27 
46 
46 
19 
gggccgucaa ucauggcaag uguccgccau acuuuguugc acgcccucgg aaugcaauac 60 
gacugua 67 
<210> SEQ ID NO 84 
<211> LENGTH, 67 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
66 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 84 
gggcgugcaa ucauggcaac gauagagcau acuuuguugg cuggccuagu uggaaauggc 60 
gguaugg 67 
<210> SEQ ID NO 85 
<211> LENGTH, 67 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 85 
ggccagccaa ucauggcaau auacacgcau acuuuguuga cggcccaguu aaacaucgca 60 
ugugcuu 67 
<210> SEQ ID NO 86 
<211> LENGTH, 43 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Combined DNA/RNA Molecule, 
Synthetic oligonucleotide 
<400> SEQUENCE, 86 
tccatgacgt tcctgacgtt tttttuugcc auguguaugu ggg 
<210> SEQ ID NO 87 
<211> LENGTH, 16 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 87 
ggaucaauca uggcaa 
<210> SEQ ID NO 88 
<211> LENGTH, 45 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Combined DNA/RNA Molecule, 
Synthetic oligonucleotide 
<400> SEQUENCE, 88 
tccatgacgt tcctgacgtt tttttcccac auacuuuguu gaucc 
<210> SEQ ID NO 89 
<211> LENGTH, 64 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 89 
43 
16 
45 
68 
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ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug 60 
uaug 64 
<210> SEQ ID NO 90 
<211> LENGTH, 54 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 90 
gguccaugac guuccugacg uuuuuuuggg ccgucaauca uggcaagugu ccgc 
<210> SEQ ID NO 91 
<211> LENGTH, 73 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 91 
54 
gguccaugac guuccugacg uuuuuuuggc cagccaauca uggcaauaua cacgcauacu 60 
uuguugacgg ccc 73 
<210> SEQ ID NO 92 
<211> LENGTH, 73 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 92 
gguccaugac guuccugacg uuuuuuuggg cgugcaauca uggcaacgau agagcauacu 60 
uuguuggcug gee 73 
<210> SEQ ID NO 93 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 93 
cauacuuugu ugcacgccc 19 
70 
What is claimed is: 
1. An artificial RNA nanostructure, comprising multiple 55 
external RNA stands and an internal RNA strand, wherein 
the internal strand and the external strands assemble to form 
3. The nanostructure of claim 1, wherein the internal 
strands and external strands assembled to form a triangle 
nanostructure, a square nanostructure, or a polygon nano-
structure. 
a polygon nanostructure, wherein a pRNA three-way junc-
tion (3 WJ) motif comprises each vertex of the nano structure; 
60 
and wherein the nanostructure comprises one or more of the 
sequences having at least 90% identity to SEQ ID NOs 1-4, 
5-9 or 10-15. 
2. The nanostructure of claim 1, wherein the multiple 65 
external RNA strands comprises three, four, or five external 
strands of RNA. 
4. The nanostructure of claim 1, wherein the nanostruc-
ture comprises a stretched intrahelical angle between HI and 
H2. 
5. The nanostructure of claim 1, further comprising one or 
more immunostimulatory motifs or adjuvants. 
6. The nanostructure of claim 5, wherein the one or more 
immunostimulatory motifs or adjuvants are selected from 
selected from one or more immunostimulatory RN As 
(isRNA) or CpG oligodeoxyribonucleotide (CpG) motifs, 
wherein the one or more CpG motifs have a sequence at least 
90% identical to SEQ ID NO: 16. 
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7. The nanostructure of claim 1, further comprising at 
least one adjuvant, antigen, and/or targeting ligand. 
8. The nanostructure of claim 1, wherein the nanostruc-
ture induces an immune response. 
9. The nanostructure of claim 8, wherein the immune 5 
response increases cytokine at least ten fold as compared to 
the adjuvant, the antigen, and/or the targeting ligand pro-
vided independently of the RNA nanostructure. 
10. The nanostructure of claim 7, wherein the antigen is 
derived from a bacteria, virus, or cell. 
10 11. The nanostructure of claim 7, wherein the antigen 
binds to a neutralizing antibody or an inhibitory antibody. 
12. The nanostructure of claim 7, wherein the antigen is 
selected from B-cell epitope, T-cell epitope, T-helper 
epitope, epitopes derived from PG120, gp4leptopes, gly-
cans, peptides, T-helper peptides, and streptavidin. 15 
13. The nanostructure of claim 7, wherein the targeting 
ligand is selected from an aptamer, a cell surface marker, 
folate, siRNA and shRNA. 
72 
14. The nanostructure of claim 7, wherein the targeting 
ligand targets B cells, T cells, dendritic cells, macrophages, 
and/or cancer cells. 
15. A composition, comprising: (a) an RNA nanostruc-
ture, wherein the RNA nanostructure is selected from RNA 
nano structure of claim 1, RNA three-way junction, and RNA 
four-way junction, and wherein the RNA nanostructure 
contains a stretched intrahelical angle between HI and H2; 
and (b) an adjuvant, an antigen, and/or a targeting ligand. 
16. The composition of claim 15, wherein the adjuvant is 
a composition comprising: (a) an RNA-oligonucleotide, 
wherein the RNA-oligonucleotide comprises single-
stranded or double stranded oligonucleotide, and wherein 
RNA-oligonucleotide is about 8-50 bases in length; and (b) 
an immunostimulatory motif, wherein the immunostimula-
tory motif is conjugated to the RNA-oligonucleotide. 
* * * * * 
